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A B S T R A C T
Background
Antidepressants are a first-line treatment for adults with moderate to severe major depression. However, many people prescribed
antidepressants for depression don’t respond fully to such medication, and little evidence is available to inform the most appropriate
’next step’ treatment for such patients, who may be referred to as having treatment-resistant depression (TRD). National Institute for
Health and Care Excellence (NICE) guidance suggests that the ’next step’ for those who do not respond to antidepressants may include
a change in the dose or type of antidepressant medication, the addition of another medication, or the start of psychotherapy. Different
types of psychotherapies may be used for TRD; evidence on these treatments is available but has not been collated to date.
Along with the sister review of pharmacological therapies for TRD, this review summarises available evidence for the effectiveness of
psychotherapies for adults (18 to 74 years) with TRD with the goal of establishing the best ’next step’ for this group.
Objectives
To assess the effectiveness of psychotherapies for adults with TRD.
Search methods
We searched theCochraneCommonMentalDisordersControlledTrialsRegister (untilMay 2016), alongwithCENTRAL,MEDLINE,
Embase, and PsycINFO via OVID (until 16 May 2017). We also searched the World Health Organization (WHO) trials portal
(ICTRP) and ClinicalTrials.gov to identify unpublished and ongoing studies. There were no date or language restrictions.
Selection criteria
We included randomised controlled trials (RCTs) with participants aged 18 to 74 years diagnosed with unipolar depression that had
not responded to minimum four weeks of antidepressant treatment at a recommended dose. We excluded studies of drug intolerance.
Acceptable diagnoses of unipolar depression were based onthe Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) or
earlier versions, International Classification of Diseases (ICD)-10, Feighner criteria, or Research Diagnostic Criteria. We included the
following comparisons.
1Psychological therapies for treatment-resistant depression in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1. Any psychological therapy versus antidepressant treatment alone, or another psychological therapy.
2. Any psychological therapy given in addition to antidepressant medication versus antidepressant treatment alone, or a psychological
therapy alone.
Primary outcomes required were change in depressive symptoms and number of dropouts from study or treatment (as a measure of
acceptability).
Data collection and analysis
We extracted data, assessed risk of bias in duplicate, and resolved disagreements through discussion or consultation with a third person.
We conducted random-effects meta-analyses when appropriate. We summarised continuous outcomes using mean differences (MDs)
or standardised mean differences (SMDs), and dichotomous outcomes using risk ratios (RRs).
Main results
We included six trials (n = 698; most participants were women approximately 40 years of age). All studies evaluated psychotherapy
plus usual care (with antidepressants) versus usual care (with antidepressants). Three studies addressed the addition of cognitive-
behavioural therapy (CBT) to usual care (n = 522), and one each evaluated intensive short-term dynamic psychotherapy (ISTDP) (n
= 60), interpersonal therapy (IPT) (n = 34), or group dialectical behavioural therapy (DBT) (n = 19) as the intervention. Most studies
were small (except one trial of CBT was large), and all studies were at high risk of detection bias for the main outcome of self-reported
depressive symptoms.
A random-effects meta-analysis of five trials (n = 575) showed that psychotherapy given in addition to usual care (vs usual care alone)
produced improvement in self-reported depressive symptoms (MD -4.07 points, 95% confidence interval (CI) -7.07 to -1.07 on the
Beck Depression Inventory (BDI) scale) over the short term (up to six months). Effects were similar when data from all six studies
were combined for self-reported depressive symptoms (SMD -0.40, 95% CI -0.65 to -0.14; n = 635). The quality of this evidence
was moderate. Similar moderate-quality evidence of benefit was seen on the Patient Health Questionnaire-9 Scale (PHQ-9) from two
studies (MD -4.66, 95% CI 8.72 to -0.59; n = 482) and on the Hamilton Depression Rating Scale (HAMD) from four studies (MD
-3.28, 95% CI -5.71 to -0.85; n = 193).
High-quality evidence shows no differential dropout (a measure of acceptability) between intervention and comparator groups over
the short term (RR 0.85, 95% CI 0.58 to 1.24; six studies; n = 698).
Moderate-quality evidence for remission from six studies (RR 1.92, 95% CI 1.46 to 2.52; n = 635) and low-quality evidence for
response from four studies (RR 1.80, 95% CI 1.2 to 2.7; n = 556) indicate that psychotherapy was beneficial as an adjunct to usual
care over the short term.
With the addition of CBT, low-quality evidence suggests lower depression scores on the BDI scale over the medium term (12 months)
(RR -3.40, 95% CI -7.21 to 0.40; two studies; n = 475) and over the long term (46 months) (RR -1.90, 95% CI -3.22 to -0.58; one
study; n = 248). Moderate-quality evidence for adjunctive CBT suggests no difference in acceptability (dropout) over the medium term
(RR 0.98, 95% CI 0.66 to 1.47; two studies; n = 549) and lower dropout over long term (RR 0.80, 95% CI 0.66 to 0.97; one study;
n = 248).
Two studies reported serious adverse events (one suicide, two hospitalisations, and two exacerbations of depression) in 4.2% of the
total sample, which occurred only in the usual care group (no events in the intervention group).
An economic analysis (conducted as part of an included study) from the UK healthcare perspective (National Health Service (NHS))
revealed that adjunctive CBT was cost-effective over nearly four years.
Authors’ conclusions
Moderate-quality evidence shows that psychotherapy added to usual care (with antidepressants) is beneficial for depressive symptoms
and for response and remission rates over the short term for patients with TRD.Medium- and long-term effects seem similarly beneficial,
although most evidence was derived from a single large trial. Psychotherapy added to usual care seems as acceptable as usual care alone.
Further evidence is needed on the effectiveness of different types of psychotherapies for patients with TRD. No evidence currently
shows whether switching to a psychotherapy is more beneficial for this patient group than continuing an antidepressant medication
regimen. Addressing this evidence gap is an important goal for researchers.
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P L A I N L A N G U A G E S U M M A R Y
Are psychological therapies effective in treating depression that did not get better with previous treatment?
Review question
Is psychological therapy an effective treatment for adults with treatment-resistant depression (TRD)?
Background
Depression is a common problem often treated with antidepressant medication. However, many people do not get better with an-
tidepressants. These patients may be said to have TRD. For these people, several different treatments can be tried - such as increasing
the dose of medicine being taken, adding another medicine, or switching to a new one. Another option is to add or switch to a
psychotherapy. Evidence indicates that psychotherapies can help in depression. What we don’t know is whether psychotherapies work
in people with TRD. This review aimed to answer this question.
Search date
Searches are current up to May 2017.
Study characteristics
We included six randomised trials (studies in which participants are allocated at random (by chance) to receive one of the treatments
being compared). These trials included 698 people and tested three different types of psychotherapy. All studies looked at whether
adding psychotherapy to current medical treatment leads to improvement in depression.
Study funding sources
All studies were funded by public research grants.
Key results
We found that patients who receive psychotherapy as well as usual care with antidepressants had fewer depressive symptoms and were
more often depression-free six months later compared with patients who continued with usual care alone. We are moderately confident
of these findings, which means that the true effect of adding CBT may be different from what we found, although findings are likely to
be close. We also found that added psychotherapy was as acceptable to patients as usual care alone. Two studies noted similar beneficial
effects after 12 months, and one study at 46 months.
Two studies reported harmful effects in people receiving usual care alone (one suicide, two people hospitalised) but none in people
receiving psychotherapy in addition to usual care.
Quality of the evidence
Because participants were aware of the treatment they had received, and because we identified only a small number of studies, we graded
the evidence as moderate in quality for findings at six months and low in quality for long-term results. This assessment might change
in the future, if higher-quality research results become available.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Psychotherapy as an adjunct to usual care compared with usual care alone for treatment- resistant depression in adults
Patient or population: adults with treatment-resistant depression
Setting: primary or secondary care
Intervention: psychotherapy with usual care
Comparison: usual care alone
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with usual care
alone
Risk with psychother-
apy as an adjunct to
usual care
Self -reported depres-
sive symptoms short
term (up to 6 months) -
BDI (BDI)
Mean depressive symp-
toms short term (up to
6 months) - BDI was 21.
1
MD 4.07 lower
(7.07 lower to 1.07
lower)
MD -4.07 (-7.01 to -1.
07)
575
(5 RCTs)
⊕⊕⊕©
MODERATEa,b
One large and 4
small studies com-
prising mainly women.
Third-wave cognit ive/
behavioural therapies
given (individual CBT in
3 studies, group DBT in
1, and individual IPT in
1)
Self -reported depres-
sive symptoms short
term (up to 6 months) -
SMD (BDI & PHQ9)
Mean depressive symp-
toms short term (up to
6 months) - BDI was 21.
1, and PHQ9 was 14.79
SMD 0.4 SD lower
(0.65 lower to 0.14
lower)
SMD -0.4 (-0.65 to -0.
14)
635 (6 RCTs) ⊕⊕⊕©
MODERATEa,b
All 6 studies combined
Observer-rated depres-
sive symptoms short
term (up to 6 months) -
PHQ-9
Mean depressive symp-
toms short term (up to
6 months) - PHQ-9 was
14.8
MD 4.66 lower
(8.72 lower to 0.59
lower)
MD -4.66 (-8.72 to -0.
59)
482
(2 RCTs)
⊕⊕⊕©
MODERATEa
One large study f rom UK
and one relat ively small
one f rom Canada
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Observer-rated depres-
sive symptoms short
term (up to 6 months) -
HAMD
Mean depressive symp-
toms short term (up to
6 months) - HAMD was
14.76
MD 3.28 lower
(5.71 lower to 0.85
lower)
MD -3.28 (-5.71 to -0.
85)
193
(4 RCTs)
⊕⊕©©
LOW
c,d
Although blinded out-
come assessment, 4
small studies each us-
ing a dif ferent type of
psychotherapy: group
DBT; ISTDP; CBT; IPT
Dropout short term (up
to 6 months)
Study populat ion RR 0.85
(0.58 to 1.24)
698
(6 RCTs)
⊕⊕⊕⊕
HIGH
Object ive out-
come; data reported in
all studies; Although a
proxy for acceptability,
it suggests that inter-
vent ion may be as ac-
ceptable as usual care
149 per 1000 (14%) 126 per 1000 (12.6%)
(86 to 184)
Response (50% re-
duct ion in depressive
symptoms f rom base-
line) short term (up to 6
months)
Study populat ion RR 1.80
(1.20 to 2.69)
556
(4 RCTs)
⊕⊕©©
LOW
a,e
-
264 per 1000 476 per 1000
(317 to 711)
Remission (< 7 on
HAMD or < 10 on BDI)
short term (up to 6
months)
Study populat ion RR 1.92
(1.46 to 2.52)
635
(6 RCTs)
⊕⊕⊕©
MODERATEa,b
One large and 5
small studies com-
prising mainly women.
Third-wave cognit ive/
behavioural therapies
given (individual CBT
in 3 studies; individual
IPT, ISTDP, and group
DBT in 1 study each)
166 per 1000 319 per 1000
(243 to 419)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; MD: mean dif ference; OR: odds rat io; RCT: randomised controlled trial; RR: risk rat io; SMD: standardised mean dif ference
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GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aOutcome assessment not blind.
bAllocat ion concealment unclear for one of the two smaller studies.
cRisk of bias due to incomplete outcome data in two of the studies.
dStudies are small. Ef fects not in the same direct ion for IPT study (n = 30).
eReport ing bias likely as less f requent ly reported than remission or mean scores.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
It has been predicted that depression will be the leading cause
of disability in high-income countries by the year 2030 (Mathers
2005). Severity of depression can be classified on the basis of Di-
agnostic and Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV), criteria as mild (five or more symptoms with minor
functional impairment), moderate (symptoms or functional im-
pairment between ’mild’ and ’severe’), or severe (most symptoms
present and interfering with functioning) (NICE 2009).
Antidepressants are often prescribed as first-line treatment for
adults with moderate to severe depression (APA 2010; NICE
2009). In England in 2010, 42.8 million prescriptions for an-
tidepressants were issued at a cost of GBP220 million (The NHS
Information Centre 2011). However, two-thirds of people do not
respond fully to such pharmacotherapy (Trivedi 2006). Such non-
response may result from intolerance to the prescribed medication
or non-adherence to the treatment regimen but may also indicate
treatment ’resistance’, whereby treatment of an adequate dose and
duration has been given. The World Psychiatric Association pro-
vided the earliest definition of treatment-’resistant’ depression: “an
absence of clinical response to treatment with a tricyclic antide-
pressant at a minimum dose of 150 mg per day of Imipramine
(or equivalent drug) for 4 to 6 weeks” (WPA 1974). Subsequently,
others suggested more complex classification systems based on
non-response tomultiple courses of treatment (Fava 2005; Fekadu
2009; Thase 1997), using terms such as ’treatment-refractory’ de-
pression and ’antidepressant-resistant’ depression to describe this
condition. For the purpose of this review, we will use the term
’treatment-resistant depression’ as this is the descriptor that has
generally represented the broadest definition of the condition.
The burden of depression is substantial, and in the UK the aver-
age service cost to the National Health Service (NHS) has been
estimated as GBP2085 per patient (McCrone 2008). Total cost of
services for depression in 2007 was estimated as GBP1.7 billion,
although these costs were dwarfed by the cost of lost productivity,
which accounted for a further GBP5.8 billion (McCrone 2008).
Similar substantial costs have been estimated for the USA, with di-
rect treatment costs estimated at USD26.1 billion and workplace
costs at a further USD51.5 billion in the year 2000 (Greenberg
2003). If up to one-third of patients have ’treatment-resistant’ de-
pression, it is clear that this condition represents a considerable
burden to patients, the NHS, and society.
Description of the intervention
First-line treatment for adults with moderate to severe depres-
sion commonly consists of an antidepressant (APA 2010; NICE
2009). Five main types of antidepressants are available: tri-
cyclic (TCAs) and related antidepressants; monoamine-oxidase in-
hibitors (MAOIs); selective serotonin reuptake inhibitors (SSRIs);
serotonin and noradrenaline reuptake inhibitors (SNRIs); and no-
radrenergic and specific serotonin antidepressants (NaSSAs). SS-
RIs are safer in terms of overdose than TCAs and tend to be bet-
ter tolerated than antidepressants of other classes. Hence, it is not
surprising that SSRIs are the most commonly prescribed antide-
pressants for treating individuals with depression (Olfson 2009;
The NHS Information Centre 2011).
No agreement has been reached on the standard approach for treat-
ment of those whose depression does not respond to antidepres-
sant medication. Guidance published by the American Psychiatric
Association (APA 2010) and the National Institute for Health
and Care Excellence (NICE 2009) suggests that the ’next step’
may include increasing the dose of the antidepressant medication,
switching to another antidepressant (within the same or in a differ-
ent pharmacological class), or augmenting treatment via another
pharmacological or psychological approach. Psychological thera-
pies thatmay be given as an adjunct can be broadly categorised into
four separate philosophical and theoretical schools: (1) psycho-
dynamic/psychoanalytical (Freud 1949; Jung 1963; Klein 1960);
(2) behavioural (Marks 1981; Skinner 1953; Watson 1924); (3)
humanistic (Maslow 1943;May 1961; Rogers 1951); and (4) cog-
nitive (Beck 1979; Lazarus 1971). In addition, ’third wave’ (Hayes
2004; Hayes 2006; Hofmann 2008) and ’integrative’ (Hollanders
2007; Klerman 1984; McCullough 1984; Ryle 1990; Shapiro
1990; Weissman 2007) psychological approaches may be used.
Elements of these approaches may overlap or may differ. For ex-
ample, cognitive-analytical therapy (CAT) incorporates elements
from several theoretical schools (Ryle 1990), whereas interpersonal
therapy for depression (IPT) is disorder-specific (Klerman 1984).
The most influential cognitive approaches have been merged with
the behavioural approach to form cognitive-behavioural therapy
(CBT) (Beck 1979; Ellis 1962), which is now viewed as a family
of therapies that draw upon a common base of cognitive and be-
havioural models of psychological disorders (Mansell 2008).
How the intervention might work
Psychological therapies such as CBT have been shown to be effec-
tive for people with depression (Churchill 2001). When a psycho-
logical therapy is given as an adjunct to pharmacological treatment,
it is hoped that the benefits gained from these different treatment
approaches may be optimised. Mechanisms of action differ among
psychological therapies. Cognitive-behavioural therapy targets the
person’s unrealistic and unhelpful negative thoughts (“dysfunc-
tional attitudes”) to improve outcomes, whereas behavioural ther-
apy focuses on changing maladaptive patterns of behaviour. In
contrast, humanistic therapy seeks to increase an individual’s self-
awareness, andpsychodynamic therapy focuses onpast experiences
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and an understanding of how these events might have influenced
the individual and his or her current thoughts and behaviours.
Why it is important to do this review
Antidepressants continue to serve as first-line treatment for many
people with depression. However, only one-third of people pre-
scribed antidepressants for depression will respond fully to such
medication (Trivedi 2006). Evidence suggests that peoplemay pre-
fer pyschotherapy to medication for depression (McHugh 2013).
Therefore, summarising the evidence for effectiveness of psycho-
logical therapies for people with treatment-resistant depression
(TRD) is important toward establishing the best ’next step’ treat-
ment for this patient group.
Several traditional reviews have examined the evidence on treat-
ment of people whose depression has not responded to antide-
pressant medication alone (e.g. Carvalho 2008; Nierenberg 2007;
Papakostas 2009). Systematic reviews on the effectiveness of com-
bination treatment for people with depression have not examined
evidence for the treatment-resistant population (Friedman 2004;
Pampallona 2004). Others have summarised the evidence for ef-
fectiveness of particular treatment strategies for those who have
not responded to antidepressants: (1) augmentation as discussed
in Carvalho 2007 with lithium - Bauer 1999 - or atypical an-
tipsychotics - Shelton 2008; (2) within- or between-class switches
(Papakostas 2008); and (3) psychological treatments (McPherson
2005). One review focused on interventions for older people (≥
55 years of age) (Cooper 2011). However, several of these reviews
included uncontrolled studies, non-randomised studies, or a com-
bination of these, as well as randomised controlled trials (RCTs)
(Carvalho 2007; Cooper 2011; McPherson 2005; Shelton 2008).
A previous systematic review of RCTs investigating pharmaco-
logical and psychological therapies for people with TRD found
no strong evidence to guide the management of such people
(Stimpson 2002). However, this review, along with others (e.g.
Bauer 1999, which summarised the evidence for lithium up to
June 1997), is out-of-date, and several relevant RCTs were pub-
lished subsequently. Another review of psychotherapies for TRD
included four controlled studies of CBT (McPherson 2005); two
studies showed benefit derived from CBT, and two found no dif-
ference between psychotherapy and control.
No agreement has been reached on the definition of ’treatment-
resistant depression’. Many studies have defined TRD as ’failure to
respond to at least two previous antidepressants’. Given continued
reliance upon antidepressants as first-line treatment, we have used
a broader and more inclusive definition of treatment resistance -
’non-response to at least four weeks of antidepressantmedication’ -
to help establish the best ’next step’ of treatment for the significant
number of people whose depression does not respond to antide-
pressant medication. The rise in antidepressant prescribing along
with increased demand for psychotherapy in recent years (BACP,
2014;McManus 2000;Middleton 2001; Pincus 1998)means that
a review of the evidence for effectiveness of psychological therapies
for people with TRD is timely. A connected review is examin-
ing pharmacological interventions for TRD (Williams 2013). To-
gether, evidence from these two linked reviews will provide a com-
prehensive evidence base of the main interventions available for
management of TRD, which will inform clinical decision-making
with regards to the best ’next step’ for adults whose depression has
not responded to first-line treatment with medication.
O B J E C T I V E S
To assess the effectiveness of psychotherapies for adults with TRD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
This review includes RCTs and cluster RCTs.
This review includes trials using a cross-over design but only data
from the first treatment phase.
Excluded from this review are trials of any other study design,
including quasi-randomised studies and non-randomised studies.
Types of participants
Age range
Participants must be 18 to 74 years of age.
We excluded any study that included some participants younger
than 75 years and some older than 74 years if the mean age of
participants was over 74 years. Similarly, we excluded any study
that included some participants younger than 18 years and some
older than 18 years if the mean age of participants was less than
18 years.
Definition of treatment-resistant depression
We defined treatment resitsant depression as “A primary diagnosis
of unipolar depression that has not responded (or has only par-
tially responded) to a minimum of four weeks of antidepressant
treatment at a recommended dose (at least 150 mg/d imipramine
or equivalent antidepressant (e.g. 20 mg/d citalopram)).”
We excluded studies that included people who had not responded
because of intolerance of antidepressant medication.
Although initiatives have sought to improve access to psycholog-
ical therapies in England and elsewhere, access to psychological
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treatment remains limited and antidepressants are often given as
first-line treatment for adults with depression. Therefore, this re-
view does not include studies of interventions intended for those
who have not responded to psychological treatment.
Diagnosis
Acceptable diagnoses of unipolar depression include those based
on criteria from DSM-IV-TR or earlier versions of this publica-
tion (APA 2000), International Classification of Diseases (ICD)-
10 (WHO 1992), Feighner criteria (Feighner 1972), or Research
Diagnostic Criteria (Spitzer 1978). We excluded studies that did
not use standardised diagnostic criteria.
Comorbidities
Excluded from this review are studies of participants with comor-
bid schizophrenia or bipolar disorder.
Also excluded are studies includingparticipantswith both unipolar
and bipolar depression unless data are available for the subgroup
of unipolar participants.
This review includes studies involving participants with comorbid
physical conditions or other psychological disorders (e.g. anxiety)
for whom psychological therapy was not being primarily used to
manage the physical illness, in other words, the focus of treatment
was TRD - not the comorbidity.
Types of interventions
Experimental interventions
1. Any psychological therapy provided as monotherapy, that
is, the intervention comprised only a psychological therapy.
2. Any psychological therapy provided as an adjunct to
antidepressant therapy, that is, the intervention was given in
addition to an antidepressant.
We grouped psychological therapies into (1) psychodynamic/psy-
choanalytical; (2) cognitive-behavioural; (3) humanistic; and (4)
integrated therapies. The ’integrated therapies’ category includes
integrative therapies such as IPT and CAT, which involve compo-
nents of different psychological therapy models. Group 2 includes
’third wave’ cognitive-behavioural therapy-based approaches.
Comparator interventions
1. An antidepressant that is included in one of five main types:
TCAs, MAOIs, SSRIs, SNRIs, and NaSSAs.
2. Another psychological therapy - grouped as above.
3. An attentional control providing the same level of support
and attention from a practitioner (as is received by those in the
experimental intervention arm) but not containing any of the
key ’active’ ingredients of the experimental intervention.
The authors of another review have included studies exam-
ining pharmacological interventions for individuals with TRD
(Williams 2013).
Types of outcome measures
Primary outcomes
1. Change in depressive symptoms as measured on rating scales
for depression, either
1. Clinician-rated depressive symptoms (e.g. Hamilton Rating
Scale for Depression (HAMD) - Hamilton 1960; Montgomery-
Asberg Depression Rating Scale (MADRS) - Montgomery
1979), or
2. Self-reported depressive symptoms (e.g. Beck Depression
Inventory (BDI) - Beck 1961; Beck 1996; other validated
measures). We analysed data on observer-rated and self-reported
outcomes separately.
2. Number of dropouts from study or treatment (all-cause
dropout) within trials.
When available, we collected data on reasons for dropout and
summarised them in narrative form.
Secondary outcomes
3. Response or remission rates, or both, based on changes in de-
pression measures - either clinician-rated (e.g. HAMD -Hamilton
1960) or self-report (e.g. BDI - Beck 1961; Beck 1996) or other
validated measures. Response is frequently quantified as at least a
50% reduction in symptoms on HAMD or BDI, but we accepted
the study’s original definition. Remission is based on the absolute
score on the depression measure. Examples of definitions of remis-
sion include scores of 7 or less on the HAMD and 10 or less on
the BDI. Again, we accepted the study authors’ original definition
4. When available, we summarised in narrative form data on im-
provements in social adjustment and social functioning including
Global Assessment of Function scores, as provided in Luborsky
1962
5. When available, we summarised in narrative form data on im-
provement in quality of life as measured on Short Form (SF)-36
(Ware 1993), Health of the Nation Outcome Scales (HoNOS)
(Wing 1994), or World Health Organization Quality of Life
(WHOQOL - WHOQOL 1998) or similar scales
6. When reported, we summarised in narrative form economic
outcomes, for example, days of work absence/ability to return
to work, number of appointments with primary care physician,
number of referrals to secondary services, and use of additional
treatments
7. When reported, we summarised in narrative form data on ad-
verse effects, for example, completed/attempted suicides
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Timing of outcome assessment
We summarised outcomes at each reported follow-up point.When
appropriate, and when the data allowed, we categorised outcomes
as short term (up to six months), medium term (seven to 12
months post treatment), and long term (longer than 12 months).
Search methods for identification of studies
Cochrane Common Mental Disorders Controlled
Trials Register (CCMDCTR)
The Cochrane Common Mental Disorders Group (CCMD)
maintains two archived clinical trials registers at its editorial base
in York, UK: a references register and a studies-based register. The
CCMDCTR-References Register contains over 40,000 reports of
RCTs examining depression, anxiety, and neurosis. Approximately
50% of these references have been tagged to individual coded tri-
als. Coded trials are held in the CCMDCTR-Studies Register, and
records are linked between the two registers through the use of
unique Study ID tags. Coding of trials is based on the EU-Psi
coding manual, which uses a controlled vocabulary (please contact
the CCMD Information Specialist for further details). Reports
of trials for inclusion in the Group’s registers are collated from
routine (weekly) generic searches of MEDLINE (1950 to 2016),
Embase (1974 to 2016), and PsycINFO (1967 to 2016); quarterly
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL); and review-specific searches of additional databases.
Reports of trials are also sourced from international trials regis-
ters via theWorld Health Organization trials portal (International
Clinical Trials Registry Platform (ICTRP)), pharmaceutical com-
panies, handsearching of key journals, conference proceedings,
and other (non-Cochrane) systematic reviews and meta-analyses.
Details of CCMD’s generic search strategies (used to identify
RCTs) can be found on the Group’s website. The Group’s Spe-
cialised Register had fallen out of date with the Editorial Group’s
move from Bristol to York in the summer of 2016.
Electronic searches
We searched theCCMDCTR-StudiesRegister using the following
terms:
Condition = ((depressi* or “affective disorder” or “mood disor-
der*”) and (“treatment-resistant” or recurrent))
We searched the CCMDCTR-References Register using a more
sensitive set of terms (keywords and subject headings) to identify
additional untagged/uncoded references:
1. depressi* [Ti, Ab, KW]
2. (*refractory* or *resistan* or *recurren*) [Ti, Ab]
3. (augment* or potentiat*) [Ti, Ab]
4. (chronicity or “chronic depress*” or “chronically depress*” or
“depressed chronic*” or “chronic major depressi*” or “chronic
affective disorder*” or “chronic mood disorder*” or (chronic* and
(relaps* or recurr*))) [Ti, Ab, KW]
5. (“persistent depress*” or “persistently depress*” or “depression
persist*” or “persistentmajor depress*” or “persistence of depress*”
or “persistence of major depress*”) [Ti, Ab]
6. (nonrespon* or non-respon* or “non respon*” or “not respon*”
or “no respon*” or “partial respon*” or “partially respon*” or “in-
complete respon*” or “incompletely respon*” or unrespon*) [Ti,
Ab]
7. (“failed to respond” or “failed to improve” or “failure to respon*”
or “failure to improve” or “failed medication*” or “antidepressant
fail*” or “treatment fail*”) [Ti, Ab]
8. (inadequate* and respon*) [Ti, Ab]
9. “treatment-resistant depression” [KW]
10. (recurrence or “recurrent depression” or “recurrent disease”)
[KW]
11. “drug resistance” [KW]
12. “treatment failure” [KW]
13. “drug potentiation” [KW]
14. augmentation [KW]
15. or/2-14
16. (1 and 15)
We applied no date or language restrictions to our search. Our
search of the CCMDCTR was up-to-date as of 18 March 2016.
We ran additional searches via the following biomedical databases
(1 January 2016 to 16 May 2017) (Appendix 1):
1. Medline/Premedline = 553
2. Embase = 546
3. CENTRAL = 477
4. Psychinfo = 246
5. Web of Science = 673
We used the term ’treatment-resistant’ or ’treatment refractory’
depression to search international trials registries, including the
WHO trials portal (ICTRP) and ClinicalTrials.gov (to 30 June
2017) (Appendix 1), to identify any additional ongoing and un-
published studies.We contactedPrincipal Investigators, whennec-
essary, to request further details of ongoing/unpublished studies
or trials reported as conference abstracts only. These searches are
up-to-date until 30 June 2017.
Searching other resources
We searched the reference lists of all included studies and other
relevant systematic reviews for studies that may meet review inclu-
sion criteria. We contacted subject experts to ensure that we had
considered for inclusion all relevant published and unpublished
studies.
Data collection and analysis
Selection of studies
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One review author (NW or PD or SI) examined titles and ab-
stracts and removed obviously irrelevant reports, then screened
study abstracts against inclusion criteria using a standardised ab-
stract screening form. In any case of uncertainty, an over-inclusive
approach was taken and the full paper was obtained, along with
full papers for studies assessed as meeting the inclusion criteria.
Two review authors screened each paper for inclusion or exclusion
from the review. If any disagreements arose, these were discussed
with a third review author. If it was not possible to determine eli-
gibility for a study, review authors added that study to the list of
those awaiting assessment and contacted trial authors to request
further information or clarification.
Review authors documented the study selection process using a
PRISMA study selection flow diagram.
Data extraction and management
Two review authors used a standardised data extraction form to
independently extract data regarding participants, interventions
and their comparators, methodological details, treatment effects
includingdropouts, andpossible biases. If any disagreements arose,
they discussed these with a third review author. The data extraction
form was piloted during the first phase of data extraction.
Review authors abstracted information related to study popula-
tions, definition of TRD, sample size, interventions, comparators,
potential biases in conduct of the trial, outcomes, follow-up, and
methods of statistical analysis.
Main planned comparisons
• Any psychological therapy versus antidepressant treatment
alone.
• Any psychological therapy versus another psychological
therapy.
• Any psychological therapy given in addition to
antidepressant medication versus antidepressant treatment alone.
• Any psychological therapy given in addition to
antidepressant medication versus a psychological therapy alone.
• Any psychological therapy versus an attention control.
For comparison 2, review authors grouped the different types of
psychological therapies according to the list given earlier.
If we identified enough studies, we planned to pool the evidence
for CBT, IPT, CAT, etc., individually within various categories for
comparisons 1, 3, and 4.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
included study using the ’Risk of bias’ tool of the Cochrane Col-
laboration (Higgins 2017). We discussed any disagreements with
a third review author. We assessed the following criteria.
1. Sequence generation: Was the allocation sequence
adequately generated?
2. Allocation concealment: Was allocation adequately
concealed?
3. Blinding of participants, study personnel, and outcome
assessors for each outcome: Was knowledge of the allocated
treatment adequately prevented during the study?
4. Incomplete outcome data for each main outcome or class of
outcomes: Were incomplete outcome data adequately addressed?
5. Selective outcome reporting: Were reports of the study free
of the suggestion of selective outcome reporting?
6. Other sources of bias: Was the study apparently free of other
problems that could put it at high risk of bias? For example, not
reporting baseline numbers, describing differential attrition,
following up only on people who continued taking medication.
Review authors extracted a description of what was reported to
have happened in each study and judged risk of bias for each
domain within and across studies, based on the following three
categories: low risk of bias; unclear risk of bias; and high risk of
bias.
When studies provided few or no details about the process of ran-
domisation, review authors contacted trial authors to seek clarifi-
cation.
Measures of treatment effect
We analysed continuous outcomes by calculating the mean dif-
ference (MD) between groups if studies used the same outcome
measure for comparison. If studies used different outcome mea-
sures to assess the same outcome, we calculated the standardised
mean difference (SMD) and 95% confidence intervals (CIs). The
SMD can be interpreted as follows: 0.2 represents a small effect,
0.5 a moderate effect, and 0.8 a large effect (Cohen 1988).
We calculated risk ratios (RRs) for dichotomous outcomes. When
overall risks were significant, we planned to calculate the number
needed to treat for an additional beneficial outcome (NNTB) or
the number needed to treat for an additional harmful outcome
(NNTH) to produce one outcome by combining the overall RR
with an estimate of prevalence of the event in the control groups
of trials.
Unit of analysis issues
Cluster-randomised trials
We planned to incorporate results from cluster RCTs into the re-
view using generic inverse variance methods (Higgins 2011).With
cluster RCTs, it is important to ensure that data were analysedwith
consideration of their clustered nature. The intracluster correla-
tion coefficient (ICC) for each trial was to be extracted. When no
such data were reported, we planned to request them from study
authors. If these data were not available, in line with the Cochrane
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Handbook for Systematic Reviews of Interventions (Higgins 2011),
we planned to use estimates from similar studies to ’correct’ data
for clustering when this had not been done.
Cross-over trials
For cross-over trials, we planned to include in the analysis only
results from the first randomised treatment period.
Studies with multiple treatment groups
Studies that include more than two arms (e.g. psychological in-
tervention (A); psychological intervention (B); and control) can
cause problems in pair-wise meta-analysis. For studies with two or
more active treatment arms, we undertook the following approach
according to whether the outcome was continuous or dichoto-
mous.
For a continuous outcome: We pooledmeans, standard deviations
(SDs), and the number of participants for each active treatment
group across treatment arms as a function of the number of par-
ticipants in each arm for comparison against the control group
(Higgins 2011).
For a dichotomous outcome: We planned to combine active treat-
ment groups into a single arm for comparison against the control
group (in terms of numbers of people with events and sample sizes)
or to split the control group equally (Higgins 2011).
Dealing with missing data
We contacted study authors to request data when missing. If an
outcome was missing for more than 50% of participants, we ex-
cluded this study from the analysis. When available, we used in-
tention-to-treat (ITT) analyses from the study reports and wrote
to study authors to request relevant unreported analyses.
Assessment of heterogeneity
We assessed heterogeneity using the Chi² test, which provides ev-
idence of variation in effect estimates beyond that of chance. The
Chi² test has low power to assess heterogeneity when included
studies are few or numbers of participants small; so we set the P
value conservatively at 0.1. We also quantified heterogeneity us-
ing the I² statistic, which calculates the percentage of variability
due to heterogeneity rather than chance. We expected, a priori,
that clinical heterogeneity between studies would be considerable;
therefore we considered I² values between 50% and 90% to rep-
resent substantial statistical heterogeneity that would need to be
explored further.
Assessment of reporting biases
We managed reporting bias by undertaking comprehensive
searches for papers in all languages and studies outside the peer-
reviewed domain. We determined outcome reporting bias for all
included studies and sought trial protocols whenever possible. If
outcome data were missing, we requested these from trial authors.
We had planned to use funnel plots to help detect reporting biases
and to conduct formal testing for small-study effects using the
Egger test (Egger 1997) if 10 or more studies were included in the
review (Higgins 2011).
Data synthesis
Given the potential for heterogeneity in the included interven-
tions, we used a random-effects model for all analyses.
This approach incorporates the assumption that different studies
are estimating different, yet related, intervention effects and takes
into account differences between studies even if no statistically sig-
nificant heterogeneity is found. We tested heterogeneity formally
using both the Chi² test and the I² statistic (as outlined above).
We sought clinical advice regarding combining treatment groups
to ensure that findings were clinically meaningful.
When a meta-analysis was not possible (e.g. owing to insufficient
data or substantial heterogeneity), we provided a narrative assess-
ment of the evidence in which we summarised the evidence ac-
cording to intervention type.
Subgroup analysis and investigation of heterogeneity
A priori, we considered the degree of treatment resistance recorded
at the point of entry to the trial a potential effect modifier. There-
fore we planned the following subgroup analyses (based on two
variables).
1. Severity of depression: classifying participants as ’non-
responders’ or ’partial responders’ at baseline
2. Length of acute treatment phase (before trial entry): four
weeks or longer, 12 weeks or longer, or six months or longer
We planned to conduct such subgroup analyses when we had
obtained data from at least 10 included studies (Higgins 2011).
Sensitivity analysis
Weplanned to conduct sensitivity analyses to explore howmuch of
the variation between studies comparing psychological therapies
for TRD was accounted for by between-study differences in:
1. study quality: allocation concealment used as a marker of
trial quality; studies that have not used allocation concealment
were excluded;
2. attrition: studies with more than 20% dropout excluded;
3. missing data: studies that have imputed missing data
excluded;
4. treatment fidelity: studies that have not measured treatment
fidelity of the psychological model excluded; or
5. publication type: studies that have not been published in
full (conference abstracts/proceedings, doctoral dissertations)
excluded.
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’Summary of findings’ table
In the original protocol, we stated that we would produce ’Sum-
mary of findings’ (SoF) tables for all relevant comparisons. How-
ever, the current recommendation to Cochrane review authors is
that they select one ’primary’ time point that theywill report for all
outcomes in the SoF tables. Following this, we present the short-
term outcome in the SoF table.
R E S U L T S
Description of studies
Results of the search
We found 4705 records via our electronic searches. We located
four further papers through complementary searches of references
and study author contacts. After removing duplicates, we screened
4515 titles and abstracts, of which we excluded 4408. However,
four studies (five references) are still awaiting full-text assessment
(Characteristics of studies awaiting classification) as, to date, we
could not obtain full-text papers and we identified one ongoing
study (Characteristics of ongoing studies), for which a full paper
is not yet available. We therefore screened 102 full-text articles.
We excluded 82 articles (pertaining to 63 studies) and provided
reasons for exclusion in Figure 1; we presented additional details
under Characteristics of excluded studies. We included in this
review 20 full-text articles pertaining to six studies. All six studies
contributed data to meta-analyses. We contacted the authors of all
included studies with regards to points of clarification and received
a response from five of the six. We also contacted two of the
authors of excluded studies to request clarification on methods
and received a response from one.
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Figure 1. Study flow diagram.
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Wehave presented details of study flow in a PRISMAflow diagram
in Figure 1.
Included studies
Six studies met all of our inclusion criteria, and we included them
in this review (see Characteristics of included studies) (Harley
2008; Nakagawa 2017; Souza 2016; Town 2017; Wiles 2007;
Wiles 2016).
Design
All six studies were parallel-group randomised trials conducted
to compare the effectiveness of psychotherapy as an adjunct to
usual care that included antidepressant medication versus usual
care alone.
Sample size
Three of the six studies were small, recruiting fewer than 50 par-
ticipants in total (Harley 2008; Souza 2016; Wiles 2007). Only
one study was a large multi-centre RCT with a total of 469 par-
ticipants randomised between two groups (Wiles 2016).
Setting
Two studies were reported from the same UK research group,
which recruited participants from general practices (primary care)
(Wiles 2007; Wiles 2016). The other four studies recruited par-
ticipants from the psychiatric outpatient departments of hospitals
(secondary care) and were conducted in the USA (Harley 2008),
Canada (Town 2017), Japan (Nakagawa 2017), and Brazil (Souza
2016).
Participants
The mean age of participants in these studies ranged from 40.6
years - in Nakagawa 2017 - to 49.3 years - in Souza 2016 - and
most participants were women (63.3% in Town 2017 to 85% in
Souza 2016); Nakagawa 2017 was the only study that recruited
more male than female participants (36%).
Interventions
All included studies addressed the same comparison: psychother-
apy as adjunct to usual care (including antidepressants) compared
with usual care alone. Trialists studied four types of psychothera-
pies: cognitive-behavioural therapy (CBT); dialectical behavioural
therapy (DBT); interpersonal therapy (IPT); and Intensive short-
term dynamic psychotherapy (ISTDP).
Three studies - one from Japan - Nakagawa 2017 - and two from
the UK - Wiles 2007 and Wiles 2016 - evaluated individual cog-
nitive-behavioural therapy (CBT) for depression using the model
proposed by Beck et al (Beck 1979). The number of sessions was
similar across these studies: 16 to 20 sessions in Nakagawa 2017,
12 to 20 sessions in Wiles 2007, and 12 to 18 sessions in Wiles
2016. In the twoUK studies, sessions lasted up to an hour andwere
provided by trained and supervised therapists representative of the
NHSpsychological therapy services (two therapists deliveredCBT
in Wiles 2007, and 11 part-time therapists delivered treatment in
Wiles 2016). In the Japanese study, individual sessions were 50
minutes in duration and were provided by four trained and super-
vised psychiatrists, one clinical psychologist, and one psychiatric
nurse. In all three studies, patients in both groups continued to
receive usual care from their treating doctors as needed during the
study. Participants were expected to continue taking antidepres-
sant medication as part of usual care.
Harley 2008 studied group dialectical behaviour therapy (DBT),
which shares key elements of CBT, namely, change-oriented cog-
nitive-behavioural strategies. Participants received 16 weekly ses-
sions, each lasting 1.5 hours, with weekly between-session home-
work assignments. The group was run by two clinical psycholo-
gists, both of whom had received DBT training and had at least 7
years experience of leading DBT skills groups.
Souza 2016 evaluated interpersonal psychotherapy (IPT) as an
adjunct to usual care. Participants received 16 individual weekly
sessions, each 40 minutes in duration. One psychiatrist and one
third-year psychiatry resident delivered therapy sessions. A senior
IPT therapist supervised the sessions weekly.
Town 2017 studied Intensive short-term dynamic psychotherapy
(ISTDP) - a brief psychotherapy format tailored to the patient’s
anxiety tolerance that helps the patient identify and address emo-
tional factors that culminate into, exacerbate, and perpetuate de-
pression.
Intervention engagement
In the pilot study of CBT (Wiles 2007), participants attended,
on average (median), 9.5 sessions (interquartile range (IQR) 2,
12]. In the US study of DBT (Harley 2008), participants did not
attend, on average, 1.8 out of 16 sessions (range 0 to 3). In the
large UK multi-centre trial (Wiles 2016), participants received an
average (median) of 12 sessions of CBT (IQR 6 to 17) by 12-
month follow-up. In total, 141 participants (60.3%) received at
least 12 sessions of CBT, and the average duration of therapy was
6.3 months (SD 3.0). In Nakagawa 2017, the mean number of
sessions completed was 15 (SD 3), with 97.5% of participants
completing the CBT course.
Participants in the Brazilian study received on average 11 sessions
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of IPT, with 70% participants receiving at least eight sessions (
Souza 2016).Harley 2008 reportedno informationon the number
of sessions. Themean number of sessions completed inTown 2017
was 16.1 (SD 6.68), and 72% (n = 24) of participants received at
least 15 sessions of ISTDP.
Intervention fidelity
Four studies also assessed the fidelity of the intervention to the
respective psychotherapy models (CBT and ISTDP) using a val-
idated rating scale completed by independent raters (Nakagawa
2017; Town 2017; Wiles 2007; Wiles 2016).
Primary outcomes
Change in depressive symptoms
All included studies reported the main outcome of change in de-
pressive symptoms. All six studies reported short-term follow-up.
Two studies reported medium-term follow-up (7 to 12 months)
(Nakagawa 2017; Wiles 2016), and one study reported long-term
(longer than 12 months) follow-up (Wiles 2016).
Five recorded outcomes using the self-report BDI scale. Three
studies used BDI version II (Beck 1996) (Nakagawa 2017; Wiles
2007; Wiles 2016), and two studies used BDI version I (Beck
1961) (Harley 2008; Souza 2016).
Two studies also reported change in depressive symptoms on the
HAMD scale (Harley 2008: Souza 2016), and Town 2017 re-
ported HAMD-GRID change scores.
Two studies also reported change in depressive symptoms on the
Patient Health Questionnaire (PHQ)-9 scale (Town 2017: Wiles
2016).
Number of dropouts
All trials reported the number of dropouts by group. When re-
ported, themost common reason for dropout was inability to con-
tact the participant, followed by withdrawal from treatment. All
reported reasons are listed in Table 1 by study and group alloca-
tion.
Secondary outcomes
Response or remission rates
All six studiesmeasured remission.Three studies defined remission
as participants scoring less than 7 on the HAMD scale (Harley
2008: Souza 2016: Town 2017); Nakagawa 2017 defined it as
scoring less than 7 on the HAMD-GRID; and Wiles 2007 and
Wiles 2016 defined remission as scoring less than 10 on the BDI-
II.
Four studies measured response (Nakagawa 2017; Souza 2016;
Wiles 2007: Wiles 2016). Both UK studies defined response as a
reduction in BDI-II score of at least 50% compared with baseline (
Wiles 2007;Wiles 2016).Nakagawa 2017 andSouza 2016 defined
response as a 50% reduction on the HAMD and HAMD-GRID
scales, respectively.
Social adjustment and social functioning
Only one trial reported social functioning, which was measured
on SAS work and LIFE work scales (Harley 2008). See Table 2.
Quality of life
Five trials measured quality of life (Nakagawa 2017; Souza 2016;
Town 2017; Wiles 2007; Wiles 2016). However, results for this
outcome from the Town 2017 study are not yet available. Wiles
2007 used an unpublished tool to measure quality of life, Town
2017 and Wiles 2016 used the SF-12 (mental and physical sub-
scales); Souza 2016 used the WHOQOL scale; and Nakagawa
2017 used the SF-36 scale. Data are reported in Table 3.
Economic outcomes
Four studies collected economic data (Nakagawa 2017; Town
2017; Wiles 2007; Wiles 2016); however results from the re-
cent studies are not yet available (Nakagawa 2017; Town 2017).
An analysis of cost-effectiveness was conducted for the large-scale
multi-centre trial (Wiles 2016), whereas in the pilot study (Wiles
2007), trial authors piloted the method of data collection and re-
ported costs per patient for the entire sample (intervention and
control groups combined).
Adverse effects
Twoof the included studies reported adverse effect data (Nakagawa
2017; Town 2017). We have presented these in Table 4.
Follow-up times reported
Harley 2008 and Wiles 2007 reported all outcome data at four
months post randomisation, and Wiles 2016 at six, 12, and (on
average) 46 months post randomisation. Souza 2016 reported all
outcomes at two, four, five, and six months of follow-up.
Nakagawa 2017 reported six and 12 months’ follow-up for all
outcomes (except economic outcomes), and Town 2017 reported
six months’ follow-up for only the main outcomes of depression
score and dropout.
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Excluded studies
We have listed excluded studies with reasons for exclusion in the
Characteristics of excluded studies table.
In total, we excluded 68 full-text articles referring to 55 studies.
Primary reasons for exclusion were as follows: study was not an
RCT (n = 8); study did not meet intervention criteria (n = 9);
age criteria were not met (n = 5); diagnostic criteria for depression
were not met (n = 7); comparison was irrelevant (n = 1); and
criteria for TRD were not met (n = 25). Those not meeting TRD
criteria included: relapse prevention and/or recurrent depression (n
= 13), did notmeet criteria for dose and duration of antidepressant
treatment (n = 13), other mood or depressive disorders (n = 7),
and psychotic disorders (n = 2) (see Characteristics of excluded
studies for detail for each study). We excluded some studies (n =
7) for more than one primary reason.
We did not include three large and well-known trials (STAR*D,
REVAMP, andTADS) in this review as they did notmeet inclusion
criteria.
The STAR*D trial did not apply diagnostic criteria at the stage of
randomisation to psychotherapy (Thase, 2007- STAR*D). This
study also originally included those who could not tolerate an-
tidepressant medication as well as those who had not responded
to medication.
For the REVAMP trial (Kocsis, 2009 - REVAMP), not all partici-
pants met the DSM diagnosis at the stage of randomisation to the
psychotherapy phase.
The TADS study used a definition of TRD that did not fit our
review: two failed attempts with treatments - one with an antide-
pressant medication, and one with either an antidepressant med-
ication or a psychological treatment (McPherson 2003 -TADS).
No criterion pertained to the dose/duration of treatment in defin-
ing a ’failed attempt,’ whereas our definition included a minimum
of four weeks’ treatment at an adequate dose. Further, studies of
interventions for those who have not responded to psychological
treatments were outside the scope of our review.
Ongoing studies
We will add one ongoing trial to the update of this review (Lynch
2015 - RO-DBT (REFRAMED).
Studies awaiting classification
Four studies (five references) await assessment and classification as
we have found no full texts to date via interlibrary loans or contact
with study authors (Checkley, 1999; Moras, 1999; Spooner 1999;
Strauss, 2002).
Risk of bias in included studies
Wehave given full details of the risk of bias for included studies un-
der Characteristics of included studies. We have provided graph-
ical representations of the overall risk of bias in included studies
for each risk of bias item in Figure 2, and for each study in Figure
3. Given the small number of studies included, we undertook no
formal comparison of reporting bias based on a funnel plot.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation (selection bias)
All six studies stated that they were randomised and reported ade-
quate random sequence generation; therefore they were at low risk
of bias for this item.
Allocation concealment (selection bias)
Five of the six studies were at low risk of bias in this domain
(Nakagawa 2017; Souza 2016; Town 2017; Wiles 2007; Wiles
2016), and one was at unclear risk (Harley 2008).
In terms of how allocation was concealed from individual recruit-
ing participants,Harley 2008 didnot provide details of themethod
of allocation concealment used; therefore we marked this one as
having unclear risk of bias for this domain. Wiles 2007 and Town
2017 used an individual independent of the recruiting researchers.
Wiles 2016 used a telephone randomisation service to conceal al-
location from those recruiting participants. Souza 2016 used se-
quentially numbered brown sealed envelopes containing the ran-
domisation sequence. Nakagawa 2017 used an automated com-
puter system for allocation.
Blinding
For psychological interventions, it is very difficult to blind patients
and therapists to the intervention being provided. Participants and
personnel providing treatment were not blind to treatment allo-
cation in any of the studies. Therefore for the domain of perfor-
mance bias, we considered all six studies to be at high risk of bias
due to lack of blinding.
For the same reason, all self-completed BDI outcome assessments
were unblinded and at high risk of detection bias. Harley 2008,
Nakagawa 2017, and Souza 2016 minimised the likelihood of ob-
server bias by blinding outcome assessors administering the ob-
server-rated (HAMD) scale. Hence, for the HAMD depression
outcome, risk of detection bias was low.
We considered risk of bias due to lack of blinding for the second
primary outcome (dropout from the study) as low for all studies,
as this is not likely to be affected by observer bias.
Incomplete outcome data
Nakagawa 2017, Wiles 2007, and Wiles 2016 were at low risk
of bias in this domain, having conducted their analyses on an
intention-to-treat (ITT) basis. Nakagawa 2017 and Wiles 2016
analysed outcomes without imputation for missing data first, then
evaluated the robustness of their findings (assumed missing at ran-
dom) by conducting sensitivity analyses imputing missing data.
Wiles 2007 used last observation carried forward in the ITT anal-
ysis. Souza 2016 indicated that researchers used an ITT approach;
however this likely referred to people who received the allocated
intervention, as the CONSORT diagram reported including only
completers in final analysis and excluding those who did not re-
ceive an allocated intervention or were lost to follow-up. Hence,
with 27% dropout, we considered this study to be at high risk
for bias for this domain. We also marked Harley 2008 as having
high risk of bias due to high dropout without an ITT analysis to
account for missing data.
Selective reporting
Three studies were at low risk of bias in this domain, as contact
with study authors provided additional or missing information
regarding planned and additional analyses (Harley 2008; Wiles
2007; Wiles 2016). Souza 2016 discussed in the study report two
new outcomes that were not listed in the protocol.We have not yet
received clarification from study authors on this; therefore we have
marked risk of bias for this study as unclear.We also considered the
two recent studies to be at unclear risk in this domain, as papers
(and communication from study authors) stated that remaining
outcomeswill be reported in future papers (Nakagawa 2017; Town
2017).
Other potential sources of bias
We considered studies at high risk of bias from other sources if
we noted any inconsistencies between papers reporting findings
that could not be explained by study protocols or study authors
in terms of differential attrition, selective follow-up, or baseline
numbers not reported. We observed no such anomalies and there-
fore considered all six studies to be at low risk of bias from other
sources.
Effects of interventions
See: Summary of findings for the main comparison
Psychotherapy as an adjunct to usual care compared with usual
care alone for treatment-resistant depression in adults - short-term
effects; Summary of findings 2 Psychotherapy as an adjunct to
usual care compared with usual care alone for treatment-resistant
depression in adults - medium- to long-term effects
Comparison 1. Psychotherapy + usual care (including
antidepressant medication) versus usual care
(including antidepressant medication)
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Primary outcomes
1.1 Depressive symptoms
Up to six months (short term)
Self-reported depressive symptoms
The pooled mean difference on the self-reported BDI scale (mean
difference (MD) -4.07, 95% confidence interval (CI) -7.01 to
-1.07; five trials, n = 575; moderate-quality evidence; Analysis
1.1) favoured the addition of psychotherapy to usual care with
antidepressant medication compared with usual care alone. Data
show little evidence of heterogeneity (I² = 27%).
Stratified by therapy type, analyses showed a similar effect for tri-
als focusing on CBT (MD -4.56, 95% CI -7.49 to -1.63; three
trials, n = 522; Analysis 1.1). The size of this effect was similar
to the overall pooled estimate because a substantial proportion of
weight (46.3 %) in the combined analysis came from the Wiles
2016 study included in this group. For group-based DBT given
in addition to usual care compared with usual care (Harley 2008),
data show a larger difference in mean BDI score but wide confi-
dence intervals and the null value of zero (MD -10.79, 95% CI
-23.83 to 2.25; one study; n = 19: Analysis 1.1). The addition
of Interpersonal psychotherapy (IPT) (Souza 2016) to usual care
showed no difference between addition of IPT to usual care com-
pared with usual care alone (MD 0.80, 95% CI -6.70 to 8.30; one
trial, n = 34; Analysis 1.1).
Two studies reported results at six months for self-reported depres-
sive symptoms on the PHQ-9 scale (Analysis 1.2) (Town 2017;
Wiles 2016). This analysis also provided evidence of the benefit of
adding psychotherapy to usual care (MD -4.66, 95% CI -8.72 to
-0.59; two trials, n = 482; moderate-quality evidence). However,
heterogeneity was substantial (I² = 73%).
Combining self-reported depressive scales across all included stud-
ies produced very similar results (SMD -0.40, 95% CI -0.65 to -
0.14; six trials, n = 635, moderate-quality evidence; Analysis 1.3).
Heterogeneity was also similar (I² = 37%).
Clinician-rated depressive symptoms
Four studies used an observer-rated instrument, the HAMD, to
measure depressive symptoms (Harley 2008; Nakagawa 2017;
Souza 2016; Town 2017). The pooled effect showed a small be-
tween-group difference favouring psychotherapy as an adjunct to
usual care (MD -3.28, 95% CI -5.71 to -0.85; four trials, n = 193;
low-quality evidence; Analysis 1.4). We noted some evidence of
heterogeneity (I² = 30%). Stratified by type of therapy, analyses
showed that effects were similar for CBT (MD-3.20, 95% CI -
5.75 to -0.65; one trial; n = 80), ISTDP (MD -5.84, 95% CI -
11.22 to -0.46; one trial, n = 60), and DBT (MD -5.81, 95% CI
-11.04 to -0.58; one trial, n = 19) in single studies but not for IPT
(MD 0.10, 95% CI -4.05 to 4.25; one trial, n = 34; Analysis 1.4).
7 to 12 months (medium term)
Self-reported depressive symptoms
Two studies examined outcomes over the medium term (
Nakagawa 2017; Wiles 2016). Those who received CBT in addi-
tion to usual care, had a BDI-II score that was lower compared
than the score for those who continuedwith usual care (MD -3.40.
95% CI -7.21 to 0.40; two trials, n = 475; low-quality evidence;
Analysis 1.5); however, the effect included the null value of zero.
Heterogeneity was moderate (I² = 41%).
Researchers found beneficial effects of adjunctive therapy in terms
of depressive symptoms measured on the PHQ-9 (Wiles 2016),
with a small difference at one year (MD -1.90 points, 95%CI -3.2
to -0.58; one trial, n = 395; low-quality evidence; Analysis 1.6).
Clinician-rated depressive symptoms
Nakagawa also reported 12-month results on the HAMD-GRID
scale. These results were similar to those for self-reported symp-
toms for this length of follow-up (MD -4.70, 95% CI -7.88 to-
1.52; one trial, n = 80; Analysis 1.7).
Longer than 12 months (long term)
Self-reported depressive symptoms
Only one trial reported long-term outcomes (Wiles 2016). This
long-term follow-up took place, on average, 46 months after ran-
domisation. At 46 months, those who had received CBT in addi-
tion to usual care had fewer symptoms of depression on the BDI
scale compared with those given usual care alone (MD -4.2, 95%
CI -7.57 to -0.83; one trial, n = 248; low-quality evidence; Analysis
1.8).
Benefit was also evident in terms of depressive symptoms onPHQ-
9 scores (MD -1.6, 95% CI -3.26 to -0.06; one study, n = 252;
low-quality evidence; Analysis 1.9).
Clinician-rated depressive symptoms
No study reported this outcome over the long term.
1.2 Dropout
Up to six months (short term)
Random-effects meta analysis combining all six studies showed
that dropout did not differ between adjunct psychotherapy and
usual care groups (RR 0.85, 95% CI 0.58 to 1.24; six trials, n =
698; high-quality evidence) (Harley 2008; Nakagawa 2017; Souza
2016; ; Town 2017; Wiles 2007; Wiles 2016). Data show no
evidence of heterogeneity (I² = 0%; Analysis 1.10).
When analysing stratification by therapy type, studies that focused
on CBT findings in terms of dropout were similar (RR 0.74, 95%
CI 0.48 to 1.16; three trials, n = 574; Analysis 1.10). For DBT,
whilst the the risk ratio for dropout favoured the control group,
confidence intervals were wide and included the null value of one
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(RR 1.27, 95% CI 0.26 to 6.28; one trial, n = 24; Analysis 1.10).
Similarly, in the single study on ISTDP (Town 2017), even though
dropout was more than twice that of the usual care group, confi-
dence intervals were wide and included the null value of one (RR
2.33, 95% CI 0.67 to 8.18; one trial, n = 60; Analysis 1.10). For
IPT psychotherapy as adjunct to usual care (Souza 2016), dropout
was lower than for usual care but confidence intervals were wide
again and included the null value of one (RR 0.68, 95% CI 0.20
to 2.33; one trial, n = 40; Analysis 1.10).
7 to 12 months (medium term)
At 12 months’ follow-up, combined results from two studies
showed no difference in dropout between intervention and usual
care groups (RR 0.98, 95% CI 0.66 to 1.47; two trials, n = 549;
moderate-quality evidence; Analysis 1.11) (Nakagawa 2017;Wiles
2016).
Longer than 12 months (long term)
At long-term follow-up (average of 46months), Wiles 2016 found
that those who received CBT as an adjunct to usual care were less
likely to drop out of the study than those randomised to usual care
(RR 0.80, 95% CI 0.66 to 0.97; one trial, n = 469; low-quality
evidence; Analysis 1.12).
Secondary outcomes
1.3 Response (50% reduction from baseline) and remission
(< 7 on HAMD or < 10 on BDI)
Up to six months (short term)
Response
Four studies reported the outcome of response over the short term,
indicating clear benefit of psychotherapy as an adjunct to usual
care when compared with usual care alone (RR 1.80, 95% CI
1.20 to 2.69; four trials, n = 556; low-quality evidence; Analysis
1.13) (Nakagawa 2017; Souza 2016; Wiles 2007; Wiles 2016).
We found no evidence of heterogeneity (I²= 0%).
The number needed to treat for an additional beneficial outcome
(NNTB) for an RR of 1.8 was 4.7 (for control group, risk of
0.264), meaning that one person on average would show response
for every 4.7 treated with added psychotherapy.
Remission
All six included studies provided data for this outcome in the
short term (Harley 2008; Nakagawa 2017; Souza 2016; Town
2017;Wiles 2007;Wiles 2016). Two studies defined remission on
the BDI scale (less than 10) (Wiles 2007; Wiles 2016), and four
studies on the HAMD scale (less than 7) (Harley 2008; Nakagawa
2017; Souza 2016; Town 2017). A random-effects meta-analysis
showed that those who received psychotherapy in addition to usual
care had a two-fold higher likelihood of remission over the short
term compared with those given usual care alone (RR 1.92, 95%
CI 1.46 to 2.52; six trials, n= 635; moderate-quality evidence;
Analysis 1.16). Data show no evidence of heterogeneity (I² = 0%).
The NNTB for an RR of 1.92 was 6.5 (for control group risk of
0.16), meaning that one person on average would reach remission
for every 6.5 treated with added psychotherapy.
7 to 12 months (medium term)
Response
In terms of the outcome of response measured over the medium
term (7 to 12 months), data from two studies show that those who
received CBT in addition to usual care were more likely to meet
criteria for response compared with those randomised to continue
with usual care (RR 1.73, 95% CI 1.42 to 2.10; two trials, n =
475; low-quality evidence; Analysis 1.14) (Nakagawa 2017; Wiles
2016).
Remission
Data on remission were available over the medium term (7 to
12 months) for two studies (Nakagawa 2017; Wiles 2016). We
found that those who received CBT in addition to usual care were
twice as likely to meet criteria for remission at 12 months’ follow-
up compared with those who were randomised to continue with
usual care (RR 1.97, 95% CI 1.51 to 2.56; two trials, n = 475;
moderate-quality evidence; Analysis 1.17).
Longer than 12 months (long term)
Response
Wiles 2016 was the only study that reported outcomes over the
long term (on average, 46 months). Again, those who received
CBT in addition to usual care were more likely to meet criteria
for response compared with those randomised to continue with
usual care (RR 1.62, 95% CI 1.13 to 2.32; one trial, n = 248; low-
quality evidence; Analysis 1.15).
Remission
The same trial reported remission outcomes over the long term
(an average of 46 months) (Wiles 2016). Those who had received
CBT in addition to usual care had a 50% increased risk of meeting
criteria for remission comparedwith those randomised to continue
with usual care, although the 95% CI included just the null value
of one (RR 1.56, 95% CI 0.97 to 2.53; one trial, n = 248; low-
quality evidence; Analysis 1.18).
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1.4 Social functioning
Harley 2008 was the only study reporting this outcome. Triailsts
used selected domains of a clinician-rated (LIFE RIFT) scale to
measure social functioning in the short term (at four months) by
assessors whowere blinded to treatment allocation. In addition, re-
searchers assessed social functioningusing two self-reported scales -
Social Adjustment Scale-Self-Report (SAS-SR) and SchwartzOut-
come Scale-10 (SOS-10). Data from 19 participants revealed that
all scales showed improved social functioning in the group given
psychotherapy as an adjunct; however effects were not consistent
across observer-rated and self-rated scales for the same domains
(Table 2).
1.5 Quality of life
Five studies measured quality of life outcomes (Nakagawa 2017;
Souza 2016; Town 2017; Wiles 2007; Wiles 2016), but only four
reported these data. Town 2017 indicated that trialists expect to
report these outcomes in a later publication. We have presented
the key results in Table 3. The QOL measure used in Wiles
2007 was an unpublished six-item instrument on which scores
could range from zero to 12, with lower scores denoting poorer
quality of life. Wiles 2007 found little evidence to suggest that
quality of life differed between intervention and usual care groups
(MD 1.20, 95% CI -1.61 to4.01). Wiles 2016 reported six-, 12-
, and 46-month data for quality of life on the SF-12 mental and
physical subscales. Results indicated improved QOL on the SF
mental subscale for all follow-ups but nodifferences on the physical
subscale. Souza 2016 used the WHOQOL scale to assess quality
of life. At six months, data showed no differences in quality of life
scores between the compared groups in physical, psychological,
social, or overall quality of life. Nakagawa 2017 reported six- and
12-month results on the SF-36 mental and physical subscales.
Study authors found no significant differences between groups at
either follow-up for any of the subscales.
1.6 Economic outcomes
AlthoughWiles 2007 reported economic data, researchers did not
compare data between the two groups. This pilot study focused
on evaluating the feasibility of collecting such data.
Wiles 2016 performed a cost utility analysis and presented an in-
cremental cost-effectiveness ratio (ICER) from the societal per-
spective over a 12-month horizon (costs in GBP for 2010 without
discounting). Analysis showed that for the base case, the addition
of CBT to usual care would be cost-effective (cost per quality-ad-
justed life-year (QALY) gain = £14,911) at the currently accepted
range for the National Health Service (NHS) (£20,000 to 30,000
perQALY). Sensitivity analyses showed that the ICER could range
from £13,006 to £29,626. When assessed at 46-month follow-up,
data show that the ICER for the base case was £5,374 (ranging
from £4,622 to £6,890 in sensitivity analyses). At a societal will-
ingness to pay of £20,000 per QALY, the net monetary benefit
per patient per year was £782, which had a probability of 0·92 of
being cost-effective.
The two recently published reports of trials did not present cost
data (Nakagawa 2017; Town 2017); however both protocols stated
that a cost-effectiveness evaluation would be performed as part of
the study, so future reports are awaited for these results.
1.7 Adverse events
Two studies reported adverse events at six and 12 months, respec-
tively (Nakagawa 2017; Town 2017). We have presented these in
Table 4. Both studies reported few adverse events only for control
group participants.
Other comparisons
No included studies addressed any of the following three compar-
isons.
1. Any psychological therapy versus antidepressant treatment
alone.
2. Any psychological therapy versus another psychological
therapy.
3. Any psychological therapy given in addition to
antidepressant medication versus a psychological therapy alone.
4. Any psychological therapy versus an attention control.
Subgroup analyses
We did not conduct planned subgroup analysis on the following
aspects because fewer than 10 studies were available for any com-
parison:
1. Severity of depression (non-responders vs partial
responders).
2. Length of acute treatment phase (12 weeks or longer vs six
months or longer).
Sensitivity analyses
We conducted preplanned sensitivity analyses for our primary out-
come of depressive symptoms as follows.
Study quality: allocation concealment
When limited to studies that adequately concealed allocation, the
pooled effect size (MD -4.66, 95% CI -7.94 to -1.37) for depres-
sive outcomes on the BDI was not materially different from that
in the main analysis (MD -5.10, 95% CI -7.89 to -2.30; Analysis
1.1).
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Attrition: more than 20% at six months
When we removed from analysis the two studies with more than
20% dropout (Harley 2008; Souza 2016), the pooled effect size
(MD -5.67, 95% CI -8.13 to -3.21) was consistent with the figure
presented earlier (MD -5.10, 95% CI -7.89 to -2.30).
Missing data: imputed missing data
No trial imputed missing data for the primary analysis, so this
analysis was not necessary.
Treatment fidelity: not measuring treatment fidelity of the
psychological model
Four studies measured treatment fidelity (Nakagawa 2017; Town
2017; Wiles 2007; Wiles 2016). Exclusion of studies that did not
measure fidelity to the psychological model yielded an estimate
of treatment effect (MD -5.67, 95% CI -8.13 to -3.21) that was
consistent with the main findings (MD -5.10, 95% CI -7.89 to -
2.30) (Harley 2008; Souza 2016).
Publication type: studies that have not been published in full
(conference abstract/proceedings, doctoral dissertation)
All studies included were available in the peer-reviewed domain;
hence this was not conducted.
Reporting bias
We minimised reporting biases in the review by including un-
published information and studies, as planned. However, with
few included studies, we could not test for small-study effect and
therefore cannot be certain that bias due to selective reporting
can be ruled out. We considered bias due to selective reporting
when grading the evidence (Summary of findings for the main
comparison; Summary of findings 2) and assigned findings a ’low’
rating for‘response’ outcome.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Psychotherapy as an adjunct to usual care compared with usual care alone for treatment- resistant depression in adults
Patient or population: adults with treatment-resistant depression
Setting: outpat ient primary or secondary care
Intervention: psychotherapy as an adjunct to usual care
Comparison: usual care alone
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with usual care
alone
Risk with psychother-
apy as an adjunct to
usual care
Self -reported depres-
sive symptoms medium
term (7 to 12 months) -
BDI
Mean depressive symp-
toms score at medium
term - BDI was 17.5
MD 3.4 lower
(7.21 lower to 0.4
higher)
- 475
(2 RCTs)
⊕⊕©©
LOWa,b
Two studies (CBT): out-
come assessment not
blind as part icipants
aware; wide conf idence
intervals
Observer-rated depres-
sive symptoms medium
term (7 to 12 months) -
PHQ-9
Mean depressive symp-
toms score at medium
term - BDI was 13
MD 1.9 lower
(3.22 lower to 0.58
lower)
- 395
(1 RCT)
⊕⊕©©
LOWa,c
Single study (CBT)
Self (pat ient)-reported
depressive symptoms
long term (longer than
12 months) - BDI
Mean depressive symp-
toms score at long term
- BDI was 23.4
MD 4.2 lower
(7.57 lower to 0.83
lower)
- 248
(1 RCT)
⊕⊕©©
LOWa,c
46-Month results
Observer-rated depres-
sive symptoms long
term (longer than 12
months) - PHQ-9
Mean depressive symp-
toms score at long term
- BDI was 11.1
MD 1.6 lower
(3.26 lower to 0.06
higher)
- 252
(1 RCT)
⊕⊕©©
LOWa,b,c
46-Month results
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Dropout medium term
(7 to 12 months)*
Study populat ion RR 0.98
(0.66 to 1.47)
549
(2 RCTs)
⊕⊕⊕©
MODERATEb
Two studies (CBT)
149 per 1000 146 per 1000
(98 to 219)
Dropout
long term (longer than
12 months)*
Study populat ion RR 0.80
(0.66 to 0.97)
469
(1 RCT)
⊕⊕©©
LOWc,d
46-Month results
523 per 1000 419 per 1000
(345 to 508)
Response (50% reduc-
t ion in BDI) medium
term (7 to 12 months)*
Study populat ion RR 1.73
(1.42 to 2.10)
475
(2 RCTs)
⊕⊕©©
LOWa,e
Two studies (CBT)
345 per 1000 434 per 1000
(489 to 724)
Response (50% re-
duct ion in BDI) long
term (longer than 12
months)*
Study populat ion RR 1.62
(1.13 to 2.32)
248
(1 RCT)
⊕⊕©©
LOWa,c
46-Month results
268 per 1000 434 per 1000
(303 to 621)
Remission (< 7 on
HAMD or < 10 on BDI)
medium term (7 to 12
months)*
Study populat ion RR 1.97
(1.51 to 2.56)
475
(2 RCTs)
⊕⊕⊕©
MODERATEa
Two studies (CBT)
223 per 1000 439 per 1000
(336 to 570)
Remission (< 7 on
HAMD or < 10 on BDI)
long term (longer than
12 months)*
Study populat ion RR 1.56
(0.97 to 2.53)
248
(1 RCT)
⊕⊕©©
LOWa,b,c
46-Month results
179 per 1000 279 per 1000
(173 to 452)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RCT: randomised controlled trial; RR: risk rat io
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GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aOutcome assessment not blind.
bWide conf idence intervals.
cSingle study data.
dResults at 46 months favour psychotherapy intervent ion when earlier results (6-month and 12-month) showed no dif ference.
eReport ing bias likely as less f requent ly reported than remission or mean scores.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
This review focused on psychological interventions for adults with
treatment-resistant depression (TRD) when psychotherapy was
the sole treatment (monotherapy) or was provided as an adjunct
to antidepressant medication. We identified no studies that ex-
amined psychotherapy as monotherapy for patients with TRD.
However, we found six studies that focused on psychotherapy as an
adjunct to usual care (which included antidepressant medication)
versus usual care alone. In three of these studies, those randomised
to intervention received cognitive-behavioural therapy (CBT); in
one study each, the intervention comprised interpersonal therapy
(IPT), intensive short-termdynamic psychotherapy (ISTDP), and
group dialectical behaviour therapy (DBT).
Summary of main results
We have summarised the findings of this review in two key tables
for short-term (Summary of findings for the main comparison)
and medium to long-term (Summary of findings 2) outcomes.
The pooledmean difference for self-reported depressive symptoms
(as measured on the Beck Depression Inventory (BDI)) based on
data from five of the six included studies shows that any psy-
chotherapy given in addition to usual care (vs usual care alone)
was beneficial over the short term (up to six months). Results were
similar for the pooled standardised mean difference for six studies.
The National Institute for Health and Care Excellence (NICE)
guidelines group previously suggested that the mimimum clini-
cally important difference (MCID) equates to at least 3 points
on the BDI (NICE 2004), and hence the benefits observed here
(mean difference -4.7 points on BDI) may be clinically relevant.
However, more recent evidence suggests thatMCID values should
be considered in terms of relative rather than absolute changes, and
that patients with TRD need larger improvements on the BDI to
report feeling better (Button 2015), although this requires further
investigation.
Quality of evidence was moderate for the short-term outcome
(Summary of findings for the main comparison). Trials provided
low- to moderate-quality evidence to support the beneficial effects
of adjunctive psychotherapy in terms of dichotomous outcomes of
response and remission over the short term (Summary of findings
for the main comparison). High-quality evidence from six pooled
studies show that dropout was not differential between interven-
tion and comparator groups. We found no evidence to support
a difference in clinician/observer-rated depressive symptoms (on
the Hamilton Depression Rating Scale (HAMD)) between treat-
ment groups, but we graded the quality of this evidence as low
(Summary of findings for the main comparison).
Only two studies reported outcomes over the medium term (up
to 12 months). These two studies provided low-quality evidence
suggesting a similarly beneficial effect for depression outcomes at
medium-term follow-up (7 to 12 months) when psychotherapy
was added to usual care. Acceptability measured by dropout also
was not different at this follow-up, and we considered the evidence
to be of moderate quality because studies were few. Only one trial
reported outcomes over the longer term. This large study based in
UK primary care provided moderate-quality evidence for longer-
term benefits of CBT as an adjunct to antidepressant medication (
Summary of findings 2). Beneficial effects, in terms of self-reported
depressive symptoms (on the BDI) and the dichotomous outcome
of response, were maintained over the long term (46 months).
Those randomised to receive the intervention were more likely
to achieve remission, although confidence intervals at 46 months
included the null value of one. At 46 months, those randomised to
receive the intervention in addition to standard care were less likely
to have dropped out of the study, with the confidence interval just
excluding the null.
Data for outcomes of quality of life, social functioning, and re-
source use were limited. Based on a single study from the UK,
addition of CBT to usual care appears cost-effective from the per-
spective of the healthcare system. For the outcome of quality of
life, we noted mixed findings, with some studies providing some
evidence for beneficial effects in terms of quality of life, and others
finding no differences between groups. We could draw no con-
clusions in terms of social functioning, as these findings relate to
only a single small study.
Overall completeness and applicability of
evidence
Our search was comprehensive; we utilised the CMDCTR’s trial
reference and studies registers, which were collated from searches
(from inception) of multiple databases, and also included assess-
ment of unpublished literature accessed by contacting study au-
thors. In addition, we screened reference lists of included stud-
ies and contacted study authors for any unpublished or ongoing
studies.
Findings from this review are applicable to adults with TRD de-
fined as “depression (meeting diagnostic criteria) that has not re-
sponded to at least 4 weeks treatment with therapeutic dose of an-
tidepressant medication”. We identified six randomised controlled
trials (RCTs) as providing evidence relevant to our review in terms
of effectiveness, acceptability, and safety of four different types of
psychotherapy. Evidence was stronger for CBTbecause of the large
UK trial with long-term follow-up but was based on only three
studies (Nakagawa 2017; Wiles 2007; Wiles 2016). The findings
for groups given DBT, ISTDP, and IPT need to be interpreted
with caution, as each set of findings is based on a single small study
(Harley 2008; Souza 2016; Town 2017, respectively). In terms of
development of policy and services for adults with TRD, it will
be important that these findings are incorporated into future revi-
sions of treatment guidelines, both in the UK (NICE) and inter-
nationally (e.g. Canadian Network for Mood and Anxiety Treat-
ments (CANMAT)).
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The age and gender distribution of participants recruited in the
included studies reflect the expected average age/gender profile of
depressed patients - women in their 30s and 40s - with the excep-
tion of Nakagawa 2017, for which most participants were men. In
terms of severity of depression, mean depression scores (BDI) in
the included studies ranged from 26 to -31, which refers to mod-
erate (17 to 29 on BDI; 20 to 28 on BDI-II) and severe (30 to 63
on BDI; 29 to 63 on BDI-II) depression categories for this scale
(Beck 1961; Beck 1996). The two UK trials recruited participants
from primary care, and the other four trials recruited outpatients
from hospital (secondary care) outpatient clinics (Harley 2008;
Nakagawa 2017; Souza 2016; Town 2017). Thus inclusion of data
from trials in different practice settings increases the generalisabil-
ity of review findings.
The six included studies were conducted in four different coun-
tries - two in the UK (n = 2) and one each in the USA, Canada,
Brazil, and Japan. Nonetheless, study findings may have limited
generalisability to other countries where the systems for delivering
mental health care are substantially different from those described
in the included studies.
We identified several gaps in the literature. We found no studies
that provided evidence on the effectiveness of a psychological ther-
apy as monotherapy for this patient group (TRD), or that com-
pared different types of psychotherapy, or active treatment versus
an attentional control.
Quality of the evidence
See Summary of findings for the main comparison and Summary
of findings 2 for details.
Study limitations
In all included studies, participants could not be blinded to treat-
ment allocation; therefore it is possible that detection bias af-
fectedmeasurements. For the observer-ratedmeasure of depression
HAMD, reported in four studies, investigators carried out blinded
outcome assessments even though participants and providers were
not blind. For the other main outcome of dropout, which was
taken to indicate acceptability, awareness of treatment status is not
expected to affect this more objective outcome as much. For the
secondary clinical outcome of response, we considered that some
reporting bias was likely.
Three studies (n = 522, including one trial with 469 participants)
examined CBT as an adjunct to antidepressant medication, and
one study each looked at IPT, ISTDP, and group DBT. All studies
were relatively small, except the large UK multi-centre CBT trial;
therefore it is not possible to draw robust conclusions about the
effectiveness of different types of psychotherapy.
Consistency of effect
Data show little statistical heterogeneity for the main outcome of
depressive symptom on BDI (27%) and HAMD (30%) scores,
but high heterogeneity (75%) in the meta-analysis of two studies
on the Patient Health Questionnaire (PHQ)-9 scale. One of six
included studies showed no benefit of psychotherapy given as an
adjunct to usual care on both BDI and HAMD scale scores (Souza
2016). This may be due to the fact that this was a relatively small
study (n = 40) that would have been underpowered to detect a
difference between groups or differences in the effectiveness of the
different types of psychotherapy provided in the included studies.
Differences in the study setting may also be relevant. As more
evidence becomes available, itmay be possible to drawmore robust
conclusions about the comparative effectiveness of different types
of psychotherapy.
Imprecision
Confidence intervals surrounding the pooled effect for both main
outcomes - depressive symptoms and dropout - were relatively nar-
row. The estimate of effect for dropout favoured the intervention
group; however, the confidence interval included the null value of
one, suggesting that psychotherapy as an adjunct to usual care was
as acceptable as usual care alone.
Indirectness
The studies included in this review were free from indirectness -
in terms of the comparison of interest (all direct comparisons) as
well as the population and interventions examined.
Publication bias
We minimised the likelihood of publication bias by searching for
and including unpublished and ongoing studies. However, we did
not examine funnel plots and did not perform a formal test of
small-study bias (Eggers test) given the small number of studies
available. This precludes any formal conclusion regarding the ab-
sence of publication bias for this review question.
Potential biases in the review process
We attempted to contact study authors to resolve queries related
to published and unpublished studies, and to obtain missing data
relevant to this review. This attempt addressed any risk of selec-
tive bias or non-reporting of outcomes in this review. One study
reported additional analyses beyond those specified in the proto-
col for secondary outcomes (response, remission) (Souza 2016).
These analyses were based on accepted definitions of response and
remission and were conducted under the assumption that all lost
to follow-up had a poor outcome, which should move the effect
estimate towards null. However, we cannot say for sure what effect
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these unplanned/additional analyses of results had on our effect
size for these two secondary review outcomes.
The major risk in terms of bias related to the fact that participants
and providers were not blinded to treatment allocation. Also, the
primary outcome common to all included studies was a measure
of self-reported depressive symptoms. This means that we cannot
exclude the possibility of performance and detection bias.
We acknowledge the potential conflict of interest arising from the
fact that three of the review authors (NW, DK, and GL) were au-
thors on two of the included studies, and we attempted tomitigate
against any unconscious bias that this may have introduced by en-
suring that other review authors (SI and PD) rechecked inclusion
and undertook data extraction and risk of bias assessment for these
studies.
Agreements and disagreements with other
studies or reviews
Four previous systematic reviews have addressed the question
examined by our review (Carvalho 2014; McIntyre 2014;
McPherson 2005; Trivedi 2011).
Of these four previous reviews, McPherson 2005 was the only re-
view that was focused on the effectiveness of psychotherapy for
TRD, similar to our review. This review used broader inclusion
criteria for TRD than we did. Review authors in the McPherson
review accepted any ’author’s description of non-response as valid’
to maximise the number of included studies because no study ful-
filled the four-week criterion for prior treatment duration that was
used in the earlier review by Stimpson 2002. McPherson 2005
also included a wider range of interventions and comparators (any
’talking’ intervention versus any other intervention) and study de-
signs (including both controlled and uncontrolled studies) com-
pared with our review, which was restricted to RCTs. McPherson
2005 found four controlled studies of CBT. These review authors
reported that two studies showed benefit and two reported no
data on effect but stated that there was no difference between psy-
chotherapy and control. This method of synthesis (vote counting)
is not recommended (Deeks 2011). Thus the review did not come
to a clear conclusion regarding the benefit of psychotherapy for
TRD but did suggest improved methodological rigour and the
need to focus in future studies on measuring outcomes important
to patients.
McIntyre 2014 included only one study (Wiles 2016); review
authors considered results from this study as providing ’com-
pelling evidence’ of effectiveness of psychotherapy of CBT type
for patients with TRD. The Trivedi 2011 review included two
of our included studies (Harley 2008; Wiles 2007), along with
three of our excluded studies (Kennedy, 2003; Scott, 2000; Thase,
2007- STAR*D). It also included one study that we excluded at
the abstract stage because it did not include patients with TRD
(Blackburn 1997). The Trivedi 2011 review thus included six tri-
als, although it counted two stages of STAR*D as two trials and
therefore refers to seven trials. It concluded that psychotherapy
is useful in TRD but effects are variable and the evidence base
is small. Carvalho 2014 included one systematic review (Trivedi
2011) and commented on the six trials included in this review,
concluding that cognitive therapies are effective in treating pa-
tients with TRD.
Two other systematic reviews that addressed the question of the
effectiveness of psychological therapy as treatment for patients
with TRD did not identify any relevant studies (Cooper 2011;
Stimpson 2002). Given that Stimpson 2002 searched the literature
up to January 2001, it is not surprising that review authors found
no studies, because all studies included in the current review were
published from 2007 onwards. The Cooper review reported not
finding any studies conducted to assess psychotherapy for TRD,
although review authors mention STAR*D under lithium aug-
mentation. The Cooper 2011 review did not present the search
strategy nor the excluded studies list, making it difficult to com-
ment on review findings.
Of these earlier reviews, only two assessed the quality of included
studies. McPherson 2005 assessed study quality using a scoring
checklist, and Cooper 2011 reported study findings using ran-
domisation as the indicator of high study quality, but neither in-
corporated study quality in the discussion nor in conclusions on
the strength of evidence.
We used preplanned random-effects meta-analyses to pool the ev-
idence on the effectiveness of psychotherapy not only in terms of
the primary outcome of depressive symptoms but also as related
to other patient important outcomes of remission and acceptabil-
ity. Hence our review provides a more comprehensive and up-to-
date assessment of relevant outcomes and provides a quantitative
summary of the magnitude of the treatment effects that can be
expected. This goes further than previous reviews, which, whilst
concluding that psychotherapy may be useful in treating patients
with TRD, did not synthesise the results quantitatively and only
advocated that better quality studies assessing the effectiveness of
psychotherapy for patients with TRD are needed.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review found moderate-quality evidence to show that psy-
chotherapy given in addition to usual care (which includes an-
tidepressant medication) for individuals with treatment-resistant
depression (TRD) has beneficial effects in terms of improvement
in depressive symptoms and response and remission rates over the
short term. Evidence of medium- and long-term beneficial effects
is similar but has been derived from two studies and one study, re-
spectively. High-quality evidence shows that adjunct psychother-
apy is as acceptable (measured with all-cause dropout) as usual
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care with antidepressant medication. In addition, cognitive-be-
havioural therapy as an adjunct to usual care appears to be cost-
effective over almost four years from the perspective of the UK
health care system (NationalHealth Service (NHS)), although this
evidence relates to a single multi-centre study.
No direct evidence on the comparative effectiveness of different
types of psychotherapies is currently available.
Implications for research
Evidence is needed on the relative effectiveness of different types
of psychological interventions for the large group of patients who
do not respond to antidepressant medication. In addition, cur-
rently no evidence is available to answer the question of whether
switching to a psychological treatment is more beneficial for this
patient group compared with continuing on existing antidepres-
sant medication. Given that many depressed patients may express
a preference for psychological treatment (McHugh 2013), it is
important that this evidence gap is addressed. Collaborative care
has been found to improve depression outcomes, and this may be
due to better monitoring resulting in more active management of
treatment, but such a model has not been evaluated in patients
with TRD. As the evidence base increases in this area, it will be
important that future researchers compare the effectiveness of dif-
ferent psychological approaches with each other, and with phar-
macological interventions. Conducting a network meta-analysis
that enables multiple treatment options to be compared simulta-
neously would inform policy and practice.
Careful consideration needs to be given to the design of future tri-
als on this topic. Many of the trials considered for inclusion in this
review did not apply diagnostic criteria at the point of randomisa-
tion; therefore we excluded them.Other trialists randomised those
who had not responded to treatment to two or more different in-
terventions. Such trials can only answer the question of whether
there is a difference in outcomes for those randomised to two dif-
ferent treatment strategies rather than informing the key question
of whether it is beneficial to try an alternative strategy (be that
switching to psychotherapy or augmenting with psychotherapy)
compared with continuing on the existing treatment.
Future studies need to incorporate additional measures of out-
comes across a range of domains that are important to patients
such as quality of life, long-term remission, and adverse effects, as
well as measuring resource use to inform discussions of cost-effec-
tiveness that are key in the context of limited healthcare resources.
Whilst the use of different scales to measure a single outcome
presents challenges for combining data, extensions to recent work
that has mapped outcomes measured on different scales - Kounali
2016 - may be useful in enabling future studies to better compare
outcomes. In addition, it is important that due consideration is
given to what patients with depression regard as the minimal clin-
ically important difference in various outcome measures - as in
Button 2015 - for powering future trials.
Finally, it is widely acknowledged that identification of adverse
effects represents a challenge in psychotherapy trials; indeed, only
two of the studies included in this review reported adverse effects.
Therefore, it is important that future studies incorporate recent
recommendations from Duggan 2014 to ensure that any negative
effects of psychotherapy are identified and reported, and that ac-
ceptability of treatment is evaluated.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Harley 2008
Methods RCT, parallel groups
Participants Recruited from outpatient clinic of a hospital
Location: USA
Criteria for depression: Structured Clinical Interview for DSM-IV diagnoses (SCID-I)
Age: range 18-65 years (mean 41.8 years)
24 participants in total (n = 18 (75%) female)
Baseline HAMD score: DBT + TAU = 16.9; waitlist/TAU = 18.9
Baseline BDI score: DBT + TAU = 27.9; waitlist/TAU = 27.4
Interventions Group I: dialectical behavioural therapy plus usual care
DBT - 16 weekly sessions, each lasting 1 hour 30 minutes, with weekly between-session
homework assignments. The group was co-led by 2 clinical psychologists trained and
experienced in group DBT
Group II: waitlist and usual care
Both groups continued antidepressant treatment as part of usual care
Outcomes Continuous measure of depressive symptoms (HamiltonDepression Scale (HAMD) and
Beck Depression Inventory (BDI) scores)
Follow-up at 16 weeks
Definition of TRD Non-response to at least 6 weeks of an adequate dose of an antidepressant
Standard effective doses were predefined by consensus of 2 senior psychiatrists with
expertise in depression
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Eligible participants were “block randomised” by gender and age
Allocation concealment (selection bias) Unclear risk No information was given regarding concealment.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and therapistswere aware of the treatment allocation
Blinding of outcome assessment (detection
bias)
Patient reported depressive symptoms
High risk Participants and therapistswere aware of the treatment allocation
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Harley 2008 (Continued)
Blinding of outcome assessment (detection
bias)
Observer rated depressive symptoms
Low risk Quote: “The independent assessors were blind to the condition
each patient had been assigned when they conducted week 0
and week 16 assessments.”
Incomplete outcome data (attrition bias)
All outcomes
High risk 23% and 18% dropout in intervention and control groups, re-
spectively. Study authors did not report any approach to dealing
with missing data and, when contacted, confirmed that no such
analyses were undertaken
Selective reporting (reporting bias) Low risk No protocol is available. Outcomes listed in methods were all
reported in results. Study author was contacted for any addi-
tional outcomes or analyses conducted, and they provided a later
publication of the study with additional (post hoc) analyses on
1 of the outcomes
Other bias Low risk No differential attrition, baseline differences, or selective follow-
up is apparent
Nakagawa 2017
Methods RCT, parallel group
Participants Recruited from outpatient departments of 2 hospitals
Location: Tokyo, Japan
Criteria for depression: DMS-IV and HAMD ≥ 16
Age: mean (SD) 39.5 (9.2) years for CBT group, 41.7 (10.7) for usual care group; range
20 to 65 years
80 participants (n = 29 (36%) female)
Baseline HAMD-GRID score: CBT + TAU = 20.9; TAU = 20.8
Baseline BDI score: CBT + TAU = 27; TAU = 27.2
Interventions Group I: cognitive-behavioural therapy in addition to usual care
CBT was delivered by 4 psychiatrists, 1 clinical psychologist, and 1 psychiatric nurse, all
of whom were trained in delivering CBT and were supervised and independently rated
by a specialist on adherence to CBT protocols. Participants could receive between 16
and 20 sessions
Group II: usual care
Investigators imposed no restrictions on the treatment that participants in the usual care
group could receive, except CBT
Both groups continued antidepressant therapy as part of usual care
Outcomes Change in clinician-rated 17-item GRID-Hamilton Depression Rating Scale (GRID-
HAMD) score at 16 weeks
Severity and change in scores of subjective depression symptoms (BDI)-II
Dropout
Proportions of responders (> 50% reduction in GRID-HAMD from baseline) and re-
mitters (< 7 GRID-HAMD)
Safety (numbers of serious adverse events)
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Nakagawa 2017 (Continued)
Quality of life (SF-36 mental; SF-36 physical)
Definition of TRD Non-response to at least 8 weeks of adequate therapeutic dosage of antidepressant med-
ication as part of usual care
Notes Closed recruitment in August 2013. Data collection to be completed in December 2014
but no publication yet
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Central computerised registration system designed for
this study (which) automatically randomises patients and gen-
erates a message noting their assigned treatment.”
Allocation concealment (selection bias) Low risk Quote: “Allocation will be concealed and stratified by site (n = 2)
with the minimisation method to balance the age and baseline
HAMD score. The cutoff for age and depression level used for
minimisation will not be disclosed until study completion.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Due to the nature of the intervention, neither the pa-
tients, the treating psychiatrists, [n]or the study therapists can
be completely blinded, but the two latter groups are strongly
instructed not to disclose the randomisation status to patients
at assessments.”
Blinding of outcome assessment (detection
bias)
Patient reported depressive symptoms
High risk Quote: “Due to the nature of the intervention, neither the pa-
tients, the treating psychiatrists, [n]or the study therapists can
be completely blinded, but the two latter groups are strongly
instructed not to disclose the randomisation status to patients
at assessments.”
Blinding of outcome assessment (detection
bias)
Observer rated depressive symptoms
Low risk Quote: “Study design uses a standardised psychiatric interview
to assess depression symptomatology by blind raters; the asses-
sors were not involved with treatment delivery and study coor-
dination and were prohibited from accessing any information
that could confer participant allocation. The success of assessor
masking was tested...percent agreement was 52 and kappa coef-
ficient was 0.00, indicating masking was successful.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary analysis was ITT with all randomised participants in-
cluded. Missing values were not imputed but were tested in sen-
sitivity analyses using imputations for departures from missing
at random
Selective reporting (reporting bias) Unclear risk Comment: Some outcomes are expected in future publications,
so we cannot judge yet
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Nakagawa 2017 (Continued)
Other bias Low risk No differential attrition, baseline differences, [n]or selective fol-
low-up apparent
Souza 2016
Methods RCT, parallel group
Participants Recruited from outpatient clinic of a hospital
Location: Brazil
Criteria for depression: DMS-IV
Age: mean (SD) 49.3 (12.3) years for IPT group, 49.18 (12.5) for usual care group
40 participants (n = 34 (85%) female)
Baseline BDI score: CBT + TAU = 31.4; TAU = 28.8
Baseline HAMD score: CBT + TAU = 19.8; TAU = 18.4
Interventions Group I: interpersonal psychotherapy (IPT) plus usual care
IPT performed according to treatment guidelines; 16 individual 40-minute weekly ses-
sions administered by third year psychiatric residents and 1 psychiatrist
Group II: Usual care - pharmacotherapy and clinical management. Clinicians were free
to choose medication(s) plus other treatments that followed standard clinical guidelines
Both groups continued antidepressant therapy as part of usual care
Outcomes Depressive symptoms: HAMD 17 as continuous score and dichotomous outcome (re-
sponse - defined as 50% reduction; remission < 7); BDI as continuous score; CGI-S as
continuous score
QOL: WHOQOL continuous score
Dropout
Definition of TRD Non-response to at least 1 trial of antidepressant medication in adequate dose and
duration. Adequate dose was defined as the equivalent of at least 75 mg of amitriptyline.
Adequate duration - at least 4 weeks
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomisation sequence generated by computer prior
to the recruitment”
Allocation concealment (selection bias) Low risk Quote: “Single randomisation was carried out by means of se-
quentially numbered brown sealed envelopes containing the ran-
domisation sequence.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No information is available, but it is likely that participants and
personnel provided/received psychotherapy and knew about it;
no placebo was used. It is possible that the clinicians who deliv-
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Souza 2016 (Continued)
ered this were blind to treatment allocation, but no information
is provided to indicate whether this was the case
Blinding of outcome assessment (detection
bias)
Patient reported depressive symptoms
High risk No information is available, but it is unlikely that participants
were blind to treatment; no placebo was used
Blinding of outcome assessment (detection
bias)
Observer rated depressive symptoms
Low risk Quote: “Investigators responsible for the outcome assessments
were blinded to the treatment assignment.”
Incomplete outcome data (attrition bias)
All outcomes
High risk 27.5% dropout; IPT group (n = 6), usual care (n = 5); although
authors stated using ITT, not all randomised participants were
analysed as per their CONSORT figure
Quote: “We performed analyses using the full data set including
all patients randomly assigned to any of the two interventions;
Considering the intention-to-treat sample the differences in re-
sponse rates and remission were not significant.”
Comment: awaiting trial author response on ITT queries
Selective reporting (reporting bias) Unclear risk The paper additionally reports response and remission, which
were not stated in the protocol. Unclear how this may affect trial
findings
Other bias Low risk No differential attrition, baseline differences, nor selective fol-
low-up apparent
Town 2017
Methods RCT, parallel group
Participants Recruited from secondary care outpatient departments
Location: Halifax, Canada
Criteria for depression: DMS-IV and HAMD ≥ 16
Age: range 18 to 65 years (mean age 38.9 years for ISTDP group, 44.2 years for usual
care group)
60 participants in total (n = 38 (63.3%) female)
Baseline score HAMD: ISTDP = 23.5; TAU = 24.03
Interventions Intensive short-term dynamic psychotherapy with treatment as usual vs standard care/
treatment as usual
Outcomes Change in depression severity (HAMD; PHQ-9)
Dropout
Quality of life (SF-12)
Cost-effectiveness
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Town 2017 (Continued)
Definition of TRD Participants with non-remitting depression following at least 1 course of antidepressants.
Participants will have had at least 1 treatment trial of antidepressants at an acceptable
therapeutic dose (length≥ 6 weeks) for the current depressive episode without adequate
response (score on the Hamilton Rating Scale for Depression ≥ 16 ) at the time of
screening interview
Notes The published paper presented only the depression outcome and dropout at 6 months
and stated that other outcomes will be presented in a following paper. Request made to
study author for unpublished data; no response yet
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “For purposes of randomisation, a researcher external
to the study team generated a permuted block randomisation
sequence using a digital random number generator.”
Allocation concealment (selection bias) Low risk Quote: “Screening assessments and enrolment were conducted
by the study research assistant who remained blind throughout
the randomisation and allocation process. Allocation was con-
ducted at the end of enrolment by an administrative assistant.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Therapists and patients could not be blinded to treat-
ment allocation.”
Blinding of outcome assessment (detection
bias)
Patient reported depressive symptoms
High risk Quote: “Therapists and patients could not be blinded to treat-
ment allocation.”
Blinding of outcome assessment (detection
bias)
Observer rated depressive symptoms
Low risk Quote: “The study research assistant was blind to treatment con-
dition; and to maintain concealment, patients were instructed
to refrain from discussing their treatment during assessments;
the study (included) use of blinded outcome ratings.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “The 60 randomised participants were included in our
primary ‘intention to treat’ analysis sample; the missing data
[were] distributed equally between the two groups.”
Selective reporting (reporting bias) Unclear risk Comment: some outcomes expected in future publications, so
we cannot judge yet
Other bias Low risk No differential attrition, baseline differences, nor selective fol-
low-up apparent
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Wiles 2007
Methods RCT, parallel groups
Participants Recruited from GP practices
Location: UK
Criteria for depression: ICD-10 and at least 15 on the BeckDepression Inventory (BDI-
II)
Age: range 18 to 65 years (mean age 45.5 years for CBT group, 45.1 years for usual care
group)
25 participants in total (n = 21 (84%) female)
Baseline BDI score: CBT + TAU = 31.3; TAU = 26.6
Interventions Group I: cognitive-behavioural therapy in addition to usual care
CBT was delivered by 2 therapists who received weekly supervision of a specialist. Par-
ticipants could receive between 12 and 20 sessions
Group II: usual care
Investigators applied no restrictions on the treatment that participants in the usual care
group could receive
Both groups continued antidepressant therapy as part of usual care
Outcomes Depressive symptoms (BDI-II) as continuous score and dichotomous outcome (response
- defined as at least a 50% reduction in BDI score)
Definition of TRD Non-response to at least 6 weeks of antidepressant treatment at British National Formu-
lary (BNF) recommended doses
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Randomisation conducted by an individual independent of the
recruitment process
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and therapistswere aware of the treatment allocation
Blinding of outcome assessment (detection
bias)
Patient reported depressive symptoms
High risk Participants were aware of the treatment allocation.
Blinding of outcome assessment (detection
bias)
Observer rated depressive symptoms
Low risk Not applicable - no observer-rated scales
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Wiles 2007 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Last observation carried forward approach used for participants
with missing data (n = 2)
Selective reporting (reporting bias) Low risk Trial protocol available. Only BDI results were reported in the
2007 publication, but data on unpublished outcomes (QOL, fi-
nal mean, SD values for BDI for each group, reasons for dropout
by group) were obtained from the study author
Other bias Low risk No differential attrition, baseline differences, nor selective fol-
low-up apparent
Wiles 2016
Methods RCT, parallel group (CoBalT trial)
Participants Recruited from GP practices
Location: UK
Criteria for depression: ICD-10 criteria for depression and at least 14 on the Beck
Depression Inventory (BDI-II)
Age: range 18 to 75 years (mean age 49.2 years for CBT group, 50.0 years for usual care
group)
469 participants in total (n = 339 (72%) female)
Baseline BDI score: CBT + TAU = 31.8; TAU = 31.8
Interventions Group I: cognitive-behavioural therapy plus usual care
Participants received a course of 12 sessions of CBT, with (up to) 6 additional sessions
if deemed necessary by the therapist. Eleven trained and supervised therapists were
representative of NHS psychological therapy services.
Sessions typically lasted 50 to 60 minutes.
At 12 months, the median number of sessions received was 12 (IQR 6 to 17)
Group II: usual care
Investigators applied no restrictions on treatment options for participants randomised
to be managed as usual by their GP. Participants could be referred for counselling or for
secondary care (including for CBT)
Both groups continued antidepressant medication as part of usual care
Outcomes Depressive symptoms were measured by (1) BeckDepression Inventory (BDI-II) - mean
scores, response (reduction inBDIof at least 50%comparedwith baseline), and remission
(BDI-II score < 10); and (2) Patient Health Questionnaire (PHQ-9)
Measures of anxiety (Generalised Anxiety Disorder Assessment (GAD-7)) and panic
(Brief PHQ)
Quality of life (QOL): SF mental and SF physical scales of the SF-12 version 2 and the
EuroQOL (EQ-5D)
Economic outcomes: primary and secondary care resource use, direct costs to NHS and
Personal Social Services, and participants’ out-of-pocket personal expenses and indirect
costs such as travel
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Wiles 2016 (Continued)
Definition of TRD Non-response to at least 6 weeks of antidepressant treatment at British National Formu-
lary (BNF) recommended doses
Notes A predefined analysis plan was agreed upon with the Trial Steering Committee. The
primary outcome for the main trial (measured at 6 months post randomisation) was a
dichotomous outcome of response (defined as at least a 50% reduction in depressive
symptoms compared with baseline), but for long-term follow-up (on average, 46months
post randomisation), the primary outcome was specified as a continuous outcome (BDI-
II score) to maximise power. This change was made at the time the request for additional
funding was submitted to the funder (6 November 2012)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation was by means of a com-
puter-generated code....Allocation was stratified
by centre and minimised (with a probability
weighting of 0.80) according to baselineBDI score
(14-19, 20-28,≥ 29); whether the general practice
had a counsellor (yes or no); previous treatment
with antidepressants (yes or no); and duration of
present episode of depression (< 1 year, 1-2 years,
≥ 2 years).”
Allocation concealment (selection bias) Low risk Quote: “randomisation...from a remote auto-
mated telephone randomisation service, which
thus ensured that the treatment allocation was
concealed from the recruiting researcher”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Because of the nature of the intervention,
it was not possible to mask participants, general
practitioners, CBT therapists, or researchers to the
treatment allocation.”
Blinding of outcome assessment (detection
bias)
Patient reported depressive symptoms
High risk Quote: “Because of the nature of the intervention,
it was not possible to mask participants, general
practitioners, CBT therapists, or researchers to the
treatment allocation.”
Blinding of outcome assessment (detection
bias)
Observer rated depressive symptoms
Low risk Not applicable - no observer-rated scales
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT done with and without imputation for miss-
ing data with similar results
Quote: “Trial dealt with any missing data at an in-
dividual item level by adopting the following rule.
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Wiles 2016 (Continued)
If > 10% of the items were incomplete, then the
data collected on that measure for that participant
were disregarded. However, if < 10% of items on
a particular measure were missing, missing item
(s) were imputed using the mean of the remaining
items (rounded to an integer). Sensitivity analyses
were conducted using the method of multiple im-
putation by chained equation (MICE) to examine
the impact of missing data on the main findings.”
Selective reporting (reporting bias) Low risk Protocol is available. Depression outcomes and
mainQOLmeasures (SF-12) are reported fully for
all time points described. Additional QOL mea-
sures collected for the economic analyses (EQ-5D-
3L, SF-6D) are not reported separately but were
used to derive QALYs
Other bias Low risk No differential attrition, baseline differences, nor
selective follow-up apparent
BDI: Beck Depression Inventory.
BNF: British National Formulary.
CBT: cognitive-behavioural therapy.
CGI-S: Clinical Global Impressions Scale.
DBT: dialectical behaviour therapy.
DSM: Diagnostic and Statistical Manual of Mental Disorders.
EQ-5D: EuroQOL Group Quality of Life Questionnaire based on five dimensions.
EQ-5D-3L: EuroQOL Group Quality of Life Questionnaire based on a three-level scale.
EuroQOL: EuroQOL Group Quality of Life Questionnaire.
GAD: generalised anxiety disorder.
GP: general practice.
HAMD: Hamilton Depression Rating Scale.
ICD: International Classification of Diseases.
IPT: interpersonal therapy.
IQR: interquartile range.
ISTDP: intensive short-term dynamic psychotherapy.
ITT: intention-to-treat.
MICE: multiple imputation by chained equation.
mg: milligram.
NHS: National Health Service.
PHQ: Patient Health Questionnaire.
QALY: quality-adjusted life-year.
QOL: quality of life.
RCT: randomised controlled trial.
SCID: Structured Clinical Interview for DSM-IV diagnoses.
SD: standard deviation.
SF: Short Form.
TAU: treatment as usual.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arnow, 2013 All participants did not meet diagnostic criteria at randomisation
Asarnow, 2011 Participants did not meet age criteria
Barnhofer, 2015 All participants did not meet diagnostic criteria at randomisation
Berner, 1974 Not an RCT
Beutel 2016 All participants did not meet diagnostic criteria at randomisation
Biesheuvel-Leliefeld, 2012 Did not meet intervention criteria; not TRD: participants currently recovered from depression
Bowie, 2013 Not TRD: no dose or duration of prior treatment provided as criteria for TRD
Britton, 2010 Not TRD: no prior antidepressant treatment
Carty 2001 Not an RCT
Chaput, 2008 Did not meet intervention criteria
Cladder-Micus, 2015 Not TRD: not all participants on prior antidepressant treatment
Crane, 2012 Not TRD: major depressive disorder
Davidson, 2005 All participants did not meet diagnostic criteria at randomisation
Dekker 2013 Not TRD: not all participants on prior antidepressant treatment
Douglas, 2015 Participants did not meet diagnostic criteria at randomisation; not TRD: recurrent mood disorder
Ducasse 2016 Participants did not meet diagnostic criteria at randomisation
Eisendrath 2016 Irrelevant comparison
Farrand, 2014 Did not meet intervention criteria; not TRD: no prior antidepressant treatment
Frank, 1987 Not an RCT
Gois, 2014 Not TRD: depression secondary to type 2 diabetes
Greenlee, 2010 Participants did not meet age criteria and did not meet diagnostic criteria at randomisation
Hides, 2006 Did not meet intervention criteria; not TRD: comorbid depression with substance abuse
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(Continued)
Hollandare, 2011 Did not meet intervention criteria. All participants did not meet diagnostic criteria at point of randomi-
sation; not TRD: ’partly remitted depression’ - no further detail
Hollon, 2014 Not TRD: recurrent or chronic depression
Huijbers, 2012 Not TRD: remitted people only
Jha, 2014 Not TRD: recurrent depression
Kearns, 2016 - DARE Not TRD: MDD (recurrent) or bipolar disorder; participants in remission
Kennard, 2006 Participants did not meet age criteria; not TRD: relapse prevention/currently remitted
Kennedy, 2003 All participants did not meet diagnostic criteria at the point of randomisation
Kocsis, 2009 - REVAMP All participants did not meet diagnostic criteria at randomisation: REVAMP
Koenig 2015 Did not meet intervention criteria; not TRD: MDD comorbid with chronic medical illness
Kuyken, 2014 Not TRD: relapse prevention
Ludman, 2016 Did not meet intervention criteria
Luyten, 2013 Not RCT; not TRD: MDD
Lynch, 2007 Not TRD: MDD or MDD with personality disorder
Maddux, 2015 Not TRD: chronic depression with comorbid personality disorder
Markowitz, 2012 Not an RCT
Martin, 2006 Not TRD: included participants with history of antidepressant medication
Martire, 2010 Participants did not meet age criteria
McPherson 2003 -TADS Not TRD: included participants without antidepressant treatment; dose and duration of treatment not
a consideration for inclusion
Melyani 2015 Not TRD: relapsing depression; no other details
Michalak 2015 Not TRD: included participants without antidepressant treatment
Moore, 1997 Not TRD: recurrent major depression
Morriss, 2010 Did not meet intervention criteria
Mota, 2014 Did not meet intervention criteria
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(Continued)
Omidi, 2013 Did not meet intervention criteria; all patients did not meet diagnostic criteria at randomisation
Otto, 2013 Not an RCT
Papadopoulos, 2014 Not an RCT
Paykel, 1999 Not TRD: prevention of relapse in partly remitted participants with residual depressive symptoms
Pearce 2016 Did not meet intervention criteria
Reynolds, 2010 Participants did not meet age criteria.
Schramm, 2011 Not TRD: chronic depression; no inclusion criteria for dose and duration of antidepressant treatment
Schramm, 2011a Not TRD: chronic depression; no inclusion criteria for dose and duration of antidepressant treatment
Schramm, 2015 Not TRD: chronic depression; no inclusion criteria for dose and duration of antidepressant treatment
Schroer, 2012 No TRD: chronic depression comorbid with chronic medical illness
Schuling 2016 Participants did not meet diagnostic criteria; not TRD: recurrent depressive disorder with or without a
current episode
Scott, 2000 Not TRD: included patients with residual depressive symptoms and with psychotic depression
Scott, 2001 All patients did not meet diagnostic criteria at randomisation; not TRD: partly remitted recent MDD
Shallcross 2016 Participants did not meet diagnostic criteria.
Teismann, 2014 Not TRD: included patients without antidepressant treatement
Thase, 2007- STAR*D Not TRD: included those who could not tolerate antidepressant medication; diagnostic criteria not
applied at randomisation
Watkins, 2009 Not an RCT
Watkins, 2011 Not TRD: MDD within past 18 months, but not in previous two months; duration of antidepressant
less than 4 weeks
MDD: major depressive disorder.
RCT: randomized controlled trial.
TRD: treatment-resistant depression.
52Psychological therapies for treatment-resistant depression in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Characteristics of studies awaiting assessment [ordered by study ID]
Checkley, 1999
Methods RCT - parallel group
Participants Unclear if TRD
Interventions Psychotherapy added to usual care with AD
Outcomes Depression
Notes No full text
Moras, 1999
Methods RCT - parallel group
Participants Unclear if TRD
Interventions Psychotherapy added to usual care with AD
Outcomes Depression
Notes No full text found
Spooner 1999
Methods RCT - parallel group
Participants Unclear if TRD
Interventions Unclear
Outcomes Depression
Notes No full text found
Strauss, 2002
Methods RCT - parallel group
Participants Unclear if TRD
Interventions Psychotherapy added to usual care with AD
Outcomes Depression
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Strauss, 2002 (Continued)
Notes No full text found
AD: antidepressant.
RCT: randomised controlled trial.
TRD: treatment-resistant depression.
Characteristics of ongoing studies [ordered by study ID]
Lynch 2015 - RO-DBT (REFRAMED)
Trial name or title ISRCTN85784627 (REFRAMED)
Methods RCT
Participants 18 years or older; TRD defined as 2 or more previous episodes of depression or chronic depression; in current
episode, participants must have taken an adequate dose of antidepressant medication for at least 6 weeks
without relief
Interventions Radically Open Dialectical Behaviour Therapy (RO-DBT) vs Treatment as Usual
Outcomes Primary outcomes:
Depression (HAMD, LIFE-RIFT) at 6 and 12 month after treatment
Health-related quality of life (EQ-5D-3 L)
Health services use/costs (AD-SUS)
Secondary outcomes:
Suicide (MSSI, SBQ)
Depression and affect (PHQ-9, PANAS)
Starting date 01/01/2012
Contact information Dr Roelie Hempel
University Road
Southampton
SO17 1BJ
United Kingdom
Notes http://www.isrctn.com/ISRCTN85784627
AD-SUS: Adult Service Use Schedule.
EQ: EuroQOL.
EQ-5D-3L: EuroQoL Group Quality of Life Questionnaire based on three-level scale.
HAMD: Hamilton Depression Scale.
LIFE-RIFT: Range of Impaired Functioning Tool.
MSSI: Modified Scale for Suicide Ideation.
PANAS: Positive and Negative Affect Schedule.
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PHQ: Patient Health Questionnaire.
RCT: randomised controlled trial.
RO-DBT: radically open dialectical behaviour therapy.
SBQ: Sedentary Behavior Questionnaire.
TRD: treatment-resistant depression.
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D A T A A N D A N A L Y S E S
Comparison 1. Psychotherapy with usual care versus usual care alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Self-reported depressive
symptoms short term (up to 6
months) - BDI
5 575 Mean Difference (IV, Random, 95% CI) -4.07 [-7.07, -1.07]
1.1 CBT with usual care vs
usual care alone
3 522 Mean Difference (IV, Random, 95% CI) -4.56 [-7.49, -1.63]
1.2 DBT with usual care vs
usual care alone
1 19 Mean Difference (IV, Random, 95% CI) -10.79 [-23.83, 2.
25]
1.3 IPT with usual care vs
usual care alone
1 34 Mean Difference (IV, Random, 95% CI) 0.80 [-6.70, 8.30]
2 Self-reported depressive
symptoms short term (up to 6
months) - PHQ-9
2 482 Mean Difference (IV, Random, 95% CI) -4.66 [-8.72, -0.59]
2.1 ISTDP with usual care vs
usual care alone
1 60 Mean Difference (IV, Random, 95% CI) -7.25 [-11.37, -3.13]
2.2 CBT with usual care vs
usual care alone
1 422 Mean Difference (IV, Random, 95% CI) -3.0 [-4.27, -1.73]
3 Self-reported depressive
symptoms short term (up to
6 months) - SMD (BDI &
PHQ-9)
6 635 Std. Mean Difference (IV, Random, 95% CI) -0.40 [-0.65, -0.14]
3.1 CBT with usual care vs
usual care alone
3 522 Std. Mean Difference (IV, Random, 95% CI) -0.35 [-0.56, -0.13]
3.2 DBT with usual care vs
usual care alone
1 19 Std. Mean Difference (IV, Random, 95% CI) -0.72 [-1.66, 0.21]
3.3 IPT with usual care vs
usual care alone
1 34 Std. Mean Difference (IV, Random, 95% CI) 0.07 [-0.60, 0.74]
3.4 ISTDP with usual care vs
usual care alone
1 60 Std. Mean Difference (IV, Random, 95% CI) -0.88 [-1.41, -0.35]
4 Clinician-rated depressive
symptoms short term (up to 6
months) - HAMD
4 193 Mean Difference (IV, Random, 95% CI) -3.28 [-5.71, -0.85]
4.1 DBT with usual care vs
usual care alone
1 19 Mean Difference (IV, Random, 95% CI) -5.81 [-11.04, -0.58]
4.2 IPT with usual care vs
usual care alone
1 34 Mean Difference (IV, Random, 95% CI) 0.10 [-4.05, 4.25]
4.3 ISTDP with usual care vs
usual care
1 60 Mean Difference (IV, Random, 95% CI) -5.84 [-11.22, -0.46]
4.4 CBT with usual care vs
usual care alone
1 80 Mean Difference (IV, Random, 95% CI) -3.20 [-5.75, -0.65]
5 Self-reported depressive
symptoms medium term (7 to
12 months) - BDI
2 475 Mean Difference (IV, Random, 95% CI) -3.40 [-7.21, 0.40]
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5.1 CBT with usual care vs
usual care alone
2 475 Mean Difference (IV, Random, 95% CI) -3.40 [-7.21, 0.40]
6 Self-reported depressive
symptoms medium term (7 to
12 months) - PHQ-9
1 395 Mean Difference (IV, Random, 95% CI) -1.90 [-3.22, -0.58]
7 Clinician-rated depressive
symptoms medium term (7 to
12 months) - HAMD
1 80 Mean Difference (IV, Random, 95% CI) -4.70 [-7.88, -1.52]
7.1 CBT with usual care vs
usual care alone
1 80 Mean Difference (IV, Random, 95% CI) -4.70 [-7.88, -1.52]
8 Self-reported depressive
symptoms long term (longer
than 12 months) - BDI
1 248 Mean Difference (IV, Random, 95% CI) -4.20 [-7.57, -0.83]
9 Self-reported depressive
symptoms long term (longer
than 12 months) - PHQ-9
1 252 Mean Difference (IV, Random, 95% CI) -1.60 [-3.26, 0.06]
10 Dropout short term (up to 6
months)
6 698 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.58, 1.24]
10.1 CBT with usual care vs
usual care alone
3 574 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.48, 1.16]
10.2 IPT with usual care vs
usual care alone
1 40 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.20, 2.33]
10.3 DBT with usual care vs
usual care alone
1 24 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.26, 6.28]
10.4 ISTDP with usual care
vs usual care alone
1 60 Risk Ratio (M-H, Random, 95% CI) 2.33 [0.67, 8.18]
11 Dropout medium term (7 to
12 months)
2 549 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.66, 1.47]
11.1 CBT with usual care vs
usual care alone
2 549 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.66, 1.47]
12 Dropout long term (longer
than 12 months)
1 469 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.66, 0.97]
13 Response (50% reduction in
depressive symptoms from
baseline) short term (up to 6
months)
4 556 Risk Ratio (M-H, Random, 95% CI) 1.80 [1.20, 2.69]
14 Response (50% reduction in
depressive symptoms from
baseline)medium term (7 to 12
months)
2 475 Risk Ratio (M-H, Random, 95% CI) 1.73 [1.42, 2.10]
15 Response (50% reduction in
depressive symptoms from
baseline) long term (longer
than 12 months)
1 248 Risk Ratio (M-H, Random, 95% CI) 1.62 [1.13, 2.32]
16 Remission (< 7 on HAMD or <
10 on BDI) short term (up to 6
months)
6 635 Risk Ratio (IV, Random, 95% CI) 1.92 [1.46, 2.52]
17 Remission (< 7 on HAMD or <
10 on BDI) medium term (7 to
12 months)
2 475 Risk Ratio (M-H, Random, 95% CI) 1.97 [1.51, 2.56]
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18 Remission (< 7 on HAMD or <
10 on BDI) long term (longer
than 12 months)
1 248 Risk Ratio (M-H, Random, 95% CI) 1.56 [0.97, 2.53]
Analysis 1.1. Comparison 1 Psychotherapy with usual care versus usual care alone, Outcome 1 Self-
reported depressive symptoms short term (up to 6 months) - BDI.
Review: Psychological therapies for treatment-resistant depression in adults
Comparison: 1 Psychotherapy with usual care versus usual care alone
Outcome: 1 Self-reported depressive symptoms short term (up to 6 months) - BDI
Study or subgroup Psychotherapy Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CBT with usual care vs usual care alone
Nakagawa 2017 40 12.5 (12.4) 40 13.3 (12.3) 21.5 % -0.80 [ -6.21, 4.61 ]
Wiles 2007 14 13.1 (11.9) 9 19.3 (5.3) 14.2 % -6.20 [ -13.33, 0.93 ]
Wiles 2016 206 18.9 (14.2) 213 24.5 (13.1) 46.3 % -5.60 [ -8.22, -2.98 ]
Subtotal (95% CI) 260 262 82.0 % -4.56 [ -7.49, -1.63 ]
Heterogeneity: Tau2 = 1.84; Chi2 = 2.60, df = 2 (P = 0.27); I2 =23%
Test for overall effect: Z = 3.05 (P = 0.0023)
2 DBT with usual care vs usual care alone
Harley 2008 10 15.1 (12.13) 9 25.89 (16.3) 4.9 % -10.79 [ -23.83, 2.25 ]
Subtotal (95% CI) 10 9 4.9 % -10.79 [ -23.83, 2.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.10)
3 IPT with usual care vs usual care alone
Souza 2016 16 23.4 (11.6) 18 22.6 (10.6) 13.1 % 0.80 [ -6.70, 8.30 ]
Subtotal (95% CI) 16 18 13.1 % 0.80 [ -6.70, 8.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
Total (95% CI) 286 289 100.0 % -4.07 [ -7.07, -1.07 ]
Heterogeneity: Tau2 = 3.27; Chi2 = 5.50, df = 4 (P = 0.24); I2 =27%
Test for overall effect: Z = 2.66 (P = 0.0078)
Test for subgroup differences: Chi2 = 2.74, df = 2 (P = 0.25), I2 =27%
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Analysis 1.2. Comparison 1 Psychotherapy with usual care versus usual care alone, Outcome 2 Self-
reported depressive symptoms short term (up to 6 months) - PHQ-9.
Review: Psychological therapies for treatment-resistant depression in adults
Comparison: 1 Psychotherapy with usual care versus usual care alone
Outcome: 2 Self-reported depressive symptoms short term (up to 6 months) - PHQ-9
Study or subgroup Psychotherapy Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ISTDP with usual care vs usual care alone
Town 2017 30 9.84 (8.4626) 30 17.09 (7.7931) 38.9 % -7.25 [ -11.37, -3.13 ]
Subtotal (95% CI) 30 30 38.9 % -7.25 [ -11.37, -3.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.45 (P = 0.00056)
2 CBT with usual care vs usual care alone
Wiles 2016 209 9.5 (6.7) 213 12.5 (6.6) 61.1 % -3.00 [ -4.27, -1.73 ]
Subtotal (95% CI) 209 213 61.1 % -3.00 [ -4.27, -1.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.63 (P < 0.00001)
Total (95% CI) 239 243 100.0 % -4.66 [ -8.72, -0.59 ]
Heterogeneity: Tau2 = 6.62; Chi2 = 3.74, df = 1 (P = 0.05); I2 =73%
Test for overall effect: Z = 2.25 (P = 0.025)
Test for subgroup differences: Chi2 = 3.74, df = 1 (P = 0.05), I2 =73%
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Analysis 1.3. Comparison 1 Psychotherapy with usual care versus usual care alone, Outcome 3 Self-
reported depressive symptoms short term (up to 6 months) - SMD (BDI & PHQ-9).
Review: Psychological therapies for treatment-resistant depression in adults
Comparison: 1 Psychotherapy with usual care versus usual care alone
Outcome: 3 Self-reported depressive symptoms short term (up to 6 months) - SMD (BDI % PHQ-9)
Study or subgroup Psychotherapy Usual care
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CBT with usual care vs usual care alone
Nakagawa 2017 40 12.5 (12.4) 40 13.3 (12.3) 20.3 % -0.06 [ -0.50, 0.37 ]
Wiles 2007 14 13.1 (11.9) 9 19.3 (5.3) 7.7 % -0.60 [ -1.46, 0.26 ]
Wiles 2016 206 18.9 (14.2) 213 24.5 (13.1) 38.2 % -0.41 [ -0.60, -0.22 ]
Subtotal (95% CI) 260 262 66.1 % -0.35 [ -0.56, -0.13 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.31, df = 2 (P = 0.32); I2 =13%
Test for overall effect: Z = 3.13 (P = 0.0017)
2 DBT with usual care vs usual care alone
Harley 2008 10 15.1 (12.13) 9 25.89 (16.3) 6.6 % -0.72 [ -1.66, 0.21 ]
Subtotal (95% CI) 10 9 6.6 % -0.72 [ -1.66, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
3 IPT with usual care vs usual care alone
Souza 2016 16 23.4 (11.6) 18 22.6 (10.6) 11.3 % 0.07 [ -0.60, 0.74 ]
Subtotal (95% CI) 16 18 11.3 % 0.07 [ -0.60, 0.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.84)
4 ISTDP with usual care vs usual care alone
Town 2017 30 9.84 (8.4626) 30 17.09 (7.7931) 15.9 % -0.88 [ -1.41, -0.35 ]
Subtotal (95% CI) 30 30 15.9 % -0.88 [ -1.41, -0.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.24 (P = 0.0012)
Total (95% CI) 316 319 100.0 % -0.40 [ -0.65, -0.14 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 7.93, df = 5 (P = 0.16); I2 =37%
Test for overall effect: Z = 2.99 (P = 0.0028)
Test for subgroup differences: Chi2 = 5.68, df = 3 (P = 0.13), I2 =47%
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Analysis 1.4. Comparison 1 Psychotherapy with usual care versus usual care alone, Outcome 4 Clinician-
rated depressive symptoms short term (up to 6 months) - HAMD.
Review: Psychological therapies for treatment-resistant depression in adults
Comparison: 1 Psychotherapy with usual care versus usual care alone
Outcome: 4 Clinician-rated depressive symptoms short term (up to 6 months) - HAMD
Study or subgroup Psychotherapy Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 DBT with usual care vs usual care alone
Harley 2008 10 11.3 (5.31) 9 17.11 (6.23) 17.0 % -5.81 [ -11.04, -0.58 ]
Subtotal (95% CI) 10 9 17.0 % -5.81 [ -11.04, -0.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.030)
2 IPT with usual care vs usual care alone
Souza 2016 16 14 (6.4) 18 13.9 (5.9) 24.0 % 0.10 [ -4.05, 4.25 ]
Subtotal (95% CI) 16 18 24.0 % 0.10 [ -4.05, 4.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
3 ISTDP with usual care vs usual care
Town 2017 30 12.9 (13.1224) 30 18.74 (7.3379) 16.3 % -5.84 [ -11.22, -0.46 ]
Subtotal (95% CI) 30 30 16.3 % -5.84 [ -11.22, -0.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P = 0.033)
4 CBT with usual care vs usual care alone
Nakagawa 2017 40 6.1 (4.5) 40 9.3 (6.9) 42.7 % -3.20 [ -5.75, -0.65 ]
Subtotal (95% CI) 40 40 42.7 % -3.20 [ -5.75, -0.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
Total (95% CI) 96 97 100.0 % -3.28 [ -5.71, -0.85 ]
Heterogeneity: Tau2 = 1.90; Chi2 = 4.30, df = 3 (P = 0.23); I2 =30%
Test for overall effect: Z = 2.65 (P = 0.0081)
Test for subgroup differences: Chi2 = 4.30, df = 3 (P = 0.23), I2 =30%
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Analysis 1.5. Comparison 1 Psychotherapy with usual care versus usual care alone, Outcome 5 Self-
reported depressive symptoms medium term (7 to 12 months) - BDI.
Review: Psychological therapies for treatment-resistant depression in adults
Comparison: 1 Psychotherapy with usual care versus usual care alone
Outcome: 5 Self-reported depressive symptoms medium term (7 to 12 months) - BDI
Study or subgroup Psychotherapy Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CBT with usual care vs usual care alone
Nakagawa 2017 40 12.5 (12.1) 40 13 (14) 30.9 % -0.50 [ -6.23, 5.23 ]
Wiles 2016 197 17 (14) 198 21.7 (12.9) 69.1 % -4.70 [ -7.36, -2.04 ]
Total (95% CI) 237 238 100.0 % -3.40 [ -7.21, 0.40 ]
Heterogeneity: Tau2 = 3.62; Chi2 = 1.70, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 1.75 (P = 0.080)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Psychotherapy with usual care versus usual care alone, Outcome 6 Self-
reported depressive symptoms medium term (7 to 12 months) - PHQ-9.
Review: Psychological therapies for treatment-resistant depression in adults
Comparison: 1 Psychotherapy with usual care versus usual care alone
Outcome: 6 Self-reported depressive symptoms medium term (7 to 12 months) - PHQ-9
Study or subgroup Psychotherapy Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Wiles 2016 197 9 (7) 198 10.9 (6.4) 100.0 % -1.90 [ -3.22, -0.58 ]
Total (95% CI) 197 198 100.0 % -1.90 [ -3.22, -0.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.81 (P = 0.0049)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Psychotherapy with usual care versus usual care alone, Outcome 7 Clinician-
rated depressive symptoms medium term (7 to 12 months) - HAMD.
Review: Psychological therapies for treatment-resistant depression in adults
Comparison: 1 Psychotherapy with usual care versus usual care alone
Outcome: 7 Clinician-rated depressive symptoms medium term (7 to 12 months) - HAMD
Study or subgroup Psychotherapy Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CBT with usual care vs usual care alone
Nakagawa 2017 40 5.4 (5.9) 40 10.1 (8.4) 100.0 % -4.70 [ -7.88, -1.52 ]
Total (95% CI) 40 40 100.0 % -4.70 [ -7.88, -1.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.90 (P = 0.0038)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Psychotherapy with usual care versus usual care alone, Outcome 8 Self-
reported depressive symptoms long term (longer than 12 months) - BDI.
Review: Psychological therapies for treatment-resistant depression in adults
Comparison: 1 Psychotherapy with usual care versus usual care alone
Outcome: 8 Self-reported depressive symptoms long term (longer than 12 months) - BDI
Study or subgroup Psychotherapy Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Wiles 2016 136 19.2 (13.8) 112 23.4 (13.2) 100.0 % -4.20 [ -7.57, -0.83 ]
Total (95% CI) 136 112 100.0 % -4.20 [ -7.57, -0.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Psychotherapy with usual care versus usual care alone, Outcome 9 Self-
reported depressive symptoms long term (longer than 12 months) - PHQ-9.
Review: Psychological therapies for treatment-resistant depression in adults
Comparison: 1 Psychotherapy with usual care versus usual care alone
Outcome: 9 Self-reported depressive symptoms long term (longer than 12 months) - PHQ-9
Study or subgroup Psychotherapy Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Wiles 2016 126 9.5 (7.1) 126 11.1 (6.3) 100.0 % -1.60 [ -3.26, 0.06 ]
Total (95% CI) 126 126 100.0 % -1.60 [ -3.26, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.058)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Psychotherapy with usual care versus usual care alone, Outcome 10 Dropout
short term (up to 6 months).
Review: Psychological therapies for treatment-resistant depression in adults
Comparison: 1 Psychotherapy with usual care versus usual care alone
Outcome: 10 Dropout short term (up to 6 months)
Study or subgroup Psychotherapy Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CBT with usual care vs usual care alone
Nakagawa 2017 2/40 2/40 4.0 % 1.00 [ 0.15, 6.76 ]
Wiles 2007 0/14 2/11 1.7 % 0.16 [ 0.01, 3.03 ]
Wiles 2016 28/234 37/235 69.9 % 0.76 [ 0.48, 1.20 ]
Subtotal (95% CI) 288 286 75.5 % 0.74 [ 0.48, 1.16 ]
Total events: 30 (Psychotherapy), 41 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.16, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
2 IPT with usual care vs usual care alone
Souza 2016 3/17 6/23 9.5 % 0.68 [ 0.20, 2.33 ]
Subtotal (95% CI) 17 23 9.5 % 0.68 [ 0.20, 2.33 ]
Total events: 3 (Psychotherapy), 6 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
3 DBT with usual care vs usual care alone
Harley 2008 3/13 2/11 5.7 % 1.27 [ 0.26, 6.28 ]
Subtotal (95% CI) 13 11 5.7 % 1.27 [ 0.26, 6.28 ]
Total events: 3 (Psychotherapy), 2 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
4 ISTDP with usual care vs usual care alone
Town 2017 7/30 3/30 9.2 % 2.33 [ 0.67, 8.18 ]
Subtotal (95% CI) 30 30 9.2 % 2.33 [ 0.67, 8.18 ]
Total events: 7 (Psychotherapy), 3 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
Total (95% CI) 348 350 100.0 % 0.85 [ 0.58, 1.24 ]
Total events: 43 (Psychotherapy), 52 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.36, df = 5 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Chi2 = 3.21, df = 3 (P = 0.36), I2 =7%
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Analysis 1.11. Comparison 1 Psychotherapy with usual care versus usual care alone, Outcome 11 Dropout
medium term (7 to 12 months).
Review: Psychological therapies for treatment-resistant depression in adults
Comparison: 1 Psychotherapy with usual care versus usual care alone
Outcome: 11 Dropout medium term (7 to 12 months)
Study or subgroup Psychotherapy Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 CBT with usual care vs usual care alone
Nakagawa 2017 3/40 4/40 7.9 % 0.75 [ 0.18, 3.14 ]
Wiles 2016 37/234 37/235 92.1 % 1.00 [ 0.66, 1.53 ]
Total (95% CI) 274 275 100.0 % 0.98 [ 0.66, 1.47 ]
Total events: 40 (Psychotherapy), 41 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Psychotherapy with usual care versus usual care alone, Outcome 12 Dropout
long term (longer than 12 months).
Review: Psychological therapies for treatment-resistant depression in adults
Comparison: 1 Psychotherapy with usual care versus usual care alone
Outcome: 12 Dropout long term (longer than 12 months)
Study or subgroup Psychotherapy Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Wiles 2016 98/234 123/235 100.0 % 0.80 [ 0.66, 0.97 ]
Total (95% CI) 234 235 100.0 % 0.80 [ 0.66, 0.97 ]
Total events: 98 (Psychotherapy), 123 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.024)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Psychotherapy with usual care versus usual care alone, Outcome 13 Response
(50% reduction in depressive symptoms from baseline) short term (up to 6 months).
Review: Psychological therapies for treatment-resistant depression in adults
Comparison: 1 Psychotherapy with usual care versus usual care alone
Outcome: 13 Response (50% reduction in depressive symptoms from baseline) short term (up to 6 months)
Study or subgroup Psychotherapy Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Nakagawa 2017 34/40 24/40 43.7 % 1.42 [ 1.07, 1.88 ]
Souza 2016 6/16 4/18 11.3 % 1.69 [ 0.58, 4.92 ]
Wiles 2007 8/14 0/9 2.1 % 11.33 [ 0.73, 175.10 ]
Wiles 2016 95/206 46/213 42.9 % 2.14 [ 1.59, 2.87 ]
Total (95% CI) 276 280 100.0 % 1.80 [ 1.20, 2.69 ]
Total events: 143 (Psychotherapy), 74 (Usual care)
Heterogeneity: Tau2 = 0.08; Chi2 = 6.90, df = 3 (P = 0.08); I2 =57%
Test for overall effect: Z = 2.85 (P = 0.0043)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Psychotherapy with usual care versus usual care alone, Outcome 14 Response
(50% reduction in depressive symptoms from baseline)medium term (7 to 12 months).
Review: Psychological therapies for treatment-resistant depression in adults
Comparison: 1 Psychotherapy with usual care versus usual care alone
Outcome: 14 Response (50% reduction in depressive symptoms from baseline)medium term (7 to 12 months)
Study or subgroup Psychotherapy Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Nakagawa 2017 33/40 20/40 33.4 % 1.65 [ 1.17, 2.32 ]
Wiles 2016 109/197 62/198 66.6 % 1.77 [ 1.39, 2.25 ]
Total (95% CI) 237 238 100.0 % 1.73 [ 1.42, 2.10 ]
Total events: 142 (Psychotherapy), 82 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 5.43 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Psychotherapy with usual care versus usual care alone, Outcome 15 Response
(50% reduction in depressive symptoms from baseline) long term (longer than 12 months).
Review: Psychological therapies for treatment-resistant depression in adults
Comparison: 1 Psychotherapy with usual care versus usual care alone
Outcome: 15 Response (50% reduction in depressive symptoms from baseline) long term (longer than 12 months)
Study or subgroup Psychotherapy Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Wiles 2016 59/136 30/112 100.0 % 1.62 [ 1.13, 2.32 ]
Total (95% CI) 136 112 100.0 % 1.62 [ 1.13, 2.32 ]
Total events: 59 (Psychotherapy), 30 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 2.61 (P = 0.0089)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Psychotherapy with usual care versus usual care alone, Outcome 16 Remission
(< 7 on HAMD or < 10 on BDI) short term (up to 6 months).
Review: Psychological therapies for treatment-resistant depression in adults
Comparison: 1 Psychotherapy with usual care versus usual care alone
Outcome: 16 Remission (< 7 on HAMD or < 10 on BDI) short term (up to 6 months)
Study or subgroup Psychotherapy Usual care Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Harley 2008 3/10 0/9 0.9 % 6.36 [ 0.37, 108.56 ]
Nakagawa 2017 28/40 16/40 40.6 % 1.75 [ 1.14, 2.69 ]
Souza 2016 5/16 3/18 4.7 % 1.88 [ 0.53, 6.63 ]
Town 2017 11/30 1/30 1.9 % 11.00 [ 1.51, 79.96 ]
Wiles 2007 6/14 1/9 2.0 % 3.86 [ 0.55, 26.96 ]
Wiles 2016 57/206 32/213 49.9 % 1.84 [ 1.25, 2.72 ]
Total (95% CI) 316 319 100.0 % 1.92 [ 1.46, 2.52 ]
Total events: 110 (Psychotherapy), 53 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.38, df = 5 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 4.66 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Psychotherapy with usual care versus usual care alone, Outcome 17 Remission
(< 7 on HAMD or < 10 on BDI) medium term (7 to 12 months).
Review: Psychological therapies for treatment-resistant depression in adults
Comparison: 1 Psychotherapy with usual care versus usual care alone
Outcome: 17 Remission (< 7 on HAMD or < 10 on BDI) medium term (7 to 12 months)
Study or subgroup Psychotherapy Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Nakagawa 2017 29/40 17/40 41.3 % 1.71 [ 1.13, 2.56 ]
Wiles 2016 78/197 36/198 58.7 % 2.18 [ 1.55, 3.07 ]
Total (95% CI) 237 238 100.0 % 1.97 [ 1.51, 2.56 ]
Total events: 107 (Psychotherapy), 53 (Usual care)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 5.07 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours psychotherapy Favours usual care
Analysis 1.18. Comparison 1 Psychotherapy with usual care versus usual care alone, Outcome 18 Remission
(< 7 on HAMD or < 10 on BDI) long term (longer than 12 months).
Review: Psychological therapies for treatment-resistant depression in adults
Comparison: 1 Psychotherapy with usual care versus usual care alone
Outcome: 18 Remission (< 7 on HAMD or < 10 on BDI) long term (longer than 12 months)
Study or subgroup Psychotherapy Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Wiles 2016 38/136 20/112 100.0 % 1.56 [ 0.97, 2.53 ]
Total (95% CI) 136 112 100.0 % 1.56 [ 0.97, 2.53 ]
Total events: 38 (Psychotherapy), 20 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.068)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Psychotherapy with usual care versus usual care alone - reasons for dropout
Study ID Total N randomised Follow-up time point,
months
Reason for dropout given
in Intervention group (psy-
chotherapy as an adjunct to
usual care)
Reason for dropout given
in control group (usual care
alone)
Harley 2008 24 4 1 difficulty finding child
care; 1 work schedule con-
flict; 1 decided group was
not a good fit
1 moved; 1 medical problem
Wiles 2016 469 6 25 not followed up
14 withdrew from study
6 lost to follow-up
4 unable to contact
1 died
22 not followed up
13 withdrew from study
6 lost to follow-up
3 unable to contact
12 36 not followed up
17 withdrew from study
17 lost to follow-up
2 died
37 not followed up
15 withdrew from study
22 lost to follow-up
Wiles 2007 25 4 NA 2 lost to follow-up
Nakagawa 2017 80 6 1 not contactable; 1 pa-
tient discontinued because
of lumbago
1 not contactable; patient
discontinued owing to fam-
ily health problem
12 1 not contactable 1 not contactable; 1 died
Town 2017 60 6 2 did not start therapy; 3 not
contactable; 2 withdrew
3 not contactable
N: number
NA: not available
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Table 2. Psychotherapy with usual care versus usual care alone for social functioning
Study ID Measure N
psy-
chother-
apy +
usual care
Final mean
psych +
usual care
SDpsych +
usual care
N
usual care
Final mean
usual care
SD
usual care
Effect size
(Cohen’s
D)a
Signif-
icance (as
reported in
the study)
Harley
2008
SAS workb 10 65.7 19.27 9 69.56 17.66 1.60 P < 0.05
Harley
2008
LIFE work
b
10 2.7 1.34 9 3.11 1.69 0.56 Not signif-
icant
Harley
2008
SAS social
or leisureb
10 64.30 12.91 9 72.56 16.21 0.77 Not signif-
icant
Harley
2008
LIFE
recreationb
10 2.7 1.06 9 3 1.19 0.49 Not signif-
icant
Harley
2008
LIFE satis-
factionb
10 2.7 0.95 9 3.33 1.19 1.12 P < 0.05
Harley
2008
SOS-10c 10 35.3 13.12 9 21.56 11.09 1.18 P < 0.05
N: number
P: P value
SD: standard deviation
aCohen’s D > 0.5 is moderate effect and > 0.8 is large effect.
bSAS-SR and LIFE-RIFT (SAS work/social recreational, LIFE work/recreation/satisfaction): Lower scores are healthier.
cSchwartz Outcome Scale-10 (SOS-10): Higher scores are healthier.
Table 3. Psychotherapy with usual care versus usual care alone for quality of life
Study ID Measure Time point
(months)
N
psychotherapy
+
usual care
N
usual care
Mean
difference
95% CI lower 95% CI upper
Wiles 2007 Unpublished
toola
4 14 9 1.20 -1.61 4.01
Wiles 2016 SF-12 mental
b
6 201 209 6 3.5 8.2
Wiles 2016 SF-12 mental
b
12 194 195 4.1 1.6 6.7
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Table 3. Psychotherapy with usual care versus usual care alone for quality of life (Continued)
Wiles 2016 SF-12 mental
b
46 132 110 3.5 0.7 6.3
Wiles 2016 SF-12 physi-
calb
6 201 209 −1.7 −3.4 0.02
Wiles 2016 SF-12 physi-
calb
12 194 195 0.3 −1.4 2
Wiles 2016 SF-12 physi-
calb
46 132 110 0.9 -2 3.7
Souza 2016 WHOQOL
overall QOLc
6 16 18 0.80 -2.67 4.27
Souza 2016 WHOQOL
physicalc
6 16 18 7.10 -3.04 17.24
Souza 2016 WHOQOL
psychologicalc
6 16 18 3.00 -8.51 14.51
Souza 2016 WHOQOL
socialc
6 16 18 6.50 -6.71 19.71
Nakagawa
2017
SF-36 mental
b
6 40 40 -2.32 -7.25 2.6
Nakagawa
2017
SF-36 mental
b
12 40 40 -1.27 -6.26 3.71
Nakagawa
2017
SF-36 physi-
calb
6 40 40 -1.17 -6.46 3.81
Nakagawa
2017
SF-36 physi-
calb
12 40 40 0.95 -4.4 6.82
CI: confidence interval
N: number
aA 6-item instrument (unpublished) on which one could score between zero and 12: lower scores denote poorer QOL
bSF physical/mental: Higher score denotes better quality of life
cWHOQOL: Higher scores denote higher quality of life.
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Table 4. Psychotherapy with usual care versus usual care alone for serious adverse events
Study ID Outcome Measure Time
point,
months
N
psy-
chother-
apy +
usual care
N
psy-
chother-
apy +
usual care
with out-
come
% N usual care N usual care
with outcome
%
Nakagawa
2017
Serious ad-
verse event
Hospital-
isation due
to depres-
sion exac-
erbation
12 40 0 0 40 2 5
Nakagawa
2017
Serious ad-
verse event
Suicide 6 40 0 0 40 1 2.5
Town
2017
Adverse
event
Increases
in depres-
sive symp-
toms
6 30 0 0 30 2 6
N: number
A P P E N D I C E S
Appendix 1. Search strategy
1 MEDLINE search strategy
Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and
Ovid MEDLINE(R) <1946 to Present>
1 Depressive Disorder, Treatment-Resistant/ (726)
2 (depress* and ((antidepress* or SSRI* or SNRI* or (serotonin adj3 (uptake or reuptake or re-uptake)) or medication* or psychotropic
or treatment* or respon*) adj2 fail*)).ti,ab,kf. (1488)
3 (depress* and ((antidepress* or SSRI* or SNRI* or (serotonin adj3 (uptake or reuptake or re-uptake)) or psychotropic medication*
or treatment*) adj2 (“no respon*” or “not respon*” or nonrespon* or non-respon* or unrespon*))).ti,ab,kf. (561)
4 (depress* adj3 (refractor* or resistan* or chronic* or persist*)).ti,ab,kf. (10275)
5 (depress* adj3 (relaps* or recurr*)).ti,kf. (1201)
6 (depress* and (augment* or potentiat*)).mp. (14786)
7 or/1-6 (26920)
8 randomized controlled trial.pt. or exp randomized controlled trial/ or exp Randomized Controlled Trials as Topic/ (570582)
9 controlled clinical trial.pt. (94063)
10 (RCT or randomi#ed or at random or (random* adj3 (assign* or allocat* or divide* or division or number*))).ti,ab,kf. (645282)
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11 ((placebo or sham or mock or fake or dummy) and (control* or group?)).ti,ab,kf. (211689)
12 double-blind*.ti,ab,kf,hw. (185041)
13 trial.ti. (181076)
14 ((cluster or crossover* or cross-over*) adj3 (random* or trial or study or control* or group?)).ti,ab,kf. (62904)
15 or/8-14 (1056236)
16 7 and 15 (3636)
17 letter/ (970850)
18 editorial/ (439091)
19 news/ (183195)
20 exp historical article/ (382466)
21 Anecdotes as topic/ (4929)
22 comment/ (690728)
23 case report/ (1883468)
24 (letter or comment*).ti. (123606)
25 exp animals/ not humans/ (4399234)
26 exp Animals, Laboratory/ (798339)
27 exp Animal Experimentation/ not (exp human experimentation/ or humans/) (4881)
28 exp Models, Animal/ (492528)
29 exp rodentia/ (2975987)
30 (rat or rats or mouse or mice or rodent*).ti. (1264597)
31 or/17-30 (8908789)
32 16 not 31 (3273)
33 (2016* or 2017*).yr,dc,ed,ep. (2581993)
34 (in-data-review or in-process or publisher).st. (1331518)
35 33 or 34 (2894741)
36 32 and 35 (553)
2 Embase search strategy
1 treatment resistant depression/
2 (depress* and ((antidepress* or SSRI* or SNRI* or (serotonin adj3 (uptake or reuptake or re-uptake)) or medication* or psychotropic
or treatment* or respon*) adj2 fail*)).ti,ab,kf.
3 (depress* and ((antidepress* or SSRI* or SNRI* or (serotonin adj3 (uptake or reuptake or re-uptake)) or psychotropic medication*
or treatment*) adj2 (“no respon*” or “not respon*” or nonrespon* or non-respon* or unrespon*))).ti,ab,kf.
4 (depress* adj3 (refractor* or resistan* or chronic* or persist*)).ti,ab,kf.
5 (depress* adj3 (relaps* or recurr*)).ti,kf.
6 (depress* and (augment* or potentiat*)).mp.
7 or/1-6
8 randomized controlled trial/ or “randomized controlled trial (topic)”/
9 crossover procedure/
10 “double blind procedure”/
11 “single-blind procedure”/
12 (RCT or randomi#ed or at random or (random* adj3 (assign* or allocat* or divide* or division or number*))).ti,ab,kf.
13 trial.ti.
14 ((cluster or crossover* or cross-over*) adj3 (random* or trial or study or control* or group?)).ti,ab,kf.
15 double-blind*.ti,ab.
16 ((placebo or sham or mock or fake or dummy) and (control* or group?)).ti,ab,kf.
17 or/8-16
18 7 and 17
19 letter.pt. or letter/
20 note.pt.
21 editorial.pt.
22 case report/ or case study/
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23 (letter or comment*).ti.
24 exp animal/ not human/
25 nonhuman/
26 exp experimental animal/
27 exp animal experiment/
28 exp animal model/
29 exp rodent/
30 (rat or rats or mouse or mice or rodent*).ti.
31 or/19-30
32 18 not 31
3 PsycINFO search strategy
1 (depress* and ((antidepress* or SSRI* or SNRI* or (serotonin adj3 (uptake or reuptake or re-uptake)) or medication* or psychotropic
or treatment* or respon*) adj2 fail*)).ti,ab,id.
2 (depress* and ((antidepress* or SSRI* or SNRI* or (serotonin adj3 (uptake or reuptake or re-uptake)) or psychotropic medication*
or treatment*) adj2 (“no respon*” or “not respon*” or nonrespon* or non-respon* or unrespon*))).ti,ab,id.
3 (depress* adj3 (refractor* or resistan* or chronic* or persist*)).ti,ab,id.
4 (depress* and (augment* or potentiat*)).mp.
5 treatment resistant depression/
6 (depress* adj3 (relaps* or recurr*)).ti,id.
7 or/1-6
8 clinical trials/
9 (RCT or randomi#ed or at random or (random* adj3 (assign* or allocat* or divide* or division or number*))).ti,ab,id.
10 double-blind*.ti,ab,id,hw.
11 ((placebo or sham or mock or fake or dummy) and (control* or group?)).ti,ab,id.
12 trial.ti.
13 ((cluster or crossover* or cross-over*) adj3 (random* or trial or study or control* or group?)).ti,ab,id.
14 or/8-13
15 7 and 14
16 (authored book or book or edited book).pt.
17 scientific communication/
18 case report/
19 (letter or comment*).ti.
20 exp animals/ or animal models/
21 (rat or rats or mouse or mice or rodent*).ti.
22 or/16-21
23 15 not 22
4 CENTRAL search strategy
#1MeSH descriptor: [Depressive Disorder, Treatment-Resistant] explode all trees
#2(depress* and ((antidepress* or SSRI* or SNRI* or (serotonin near/3 (uptake or reuptake or re-uptake)) ormedication* or psychotropic
or treatment* or respon*) near/2 fail*)):ti,ab,kw
#3(depress* and ((antidepress* or SSRI* or SNRI* or (serotonin near/3 (uptake or reuptake or re-uptake)) or “psychotropic medication”
or “psychotropic medications” or treatment*) near/2 (“no respon*” or “not respon*” or nonrespon* or non-respon* or unrespon*))):
ti,ab,kw
#4(depress* near/3 (refractor* or resistan* or chronic* or persist*)):ti,ab,kw
#5(depress* near/3 (relaps* or recurr*)):ti,kw
#6(depress* and (augment* or potentiat*)):ti,ab,kw
#7#1 or #2 or #3 or #4 or #5 or #6
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5 Web of Science search strategy
# 15 #11 not #14
# 14 #13 OR #12
# 13 TS=((animal* near/2 experiment*) or (animal* near/2 model*) or (animal* near/2 laborator*))
# 12 TI= (rat or rats or mouse or mice or rodent* or animal* or comment* or letter or “case study” or “case report” or anecdote* or
editorial* or news )
# 11 #10 AND #6
# 10 #9 OR #8 OR #7
# 9 TI= trial
# 8TS= (RCT or randomized or randomised or “at random” or (random* near/3 (assign* or allocat* or divide* or division or number*)))
# 7 TS= ((controlled near/2 “clinical trial”) or double-blind* or ((placebo or sham or mock or fake or dummy) and (control* or group?
)) or ((cluster or crossover* or cross-over*) near/3 (random* or trial or study or control* or group?)))
# 6 #5 OR #4 OR #3 OR #2 OR #1
# 5 TS=(depress* and (augment* or potentiat*))
# 4 TS=(depress* near/3 (relaps* or recurr*))
# 3 TS=(depress* near/3 (refractor* or resistan* or chronic* or persist*))
# 2 TS=(depress* and ((antidepress* or SSRI* or SNRI* or (serotonin near/3 (uptake or reuptake or re-uptake)) or “psychotropic
medication” or “psychotropic medications” or treatment*) near/2 (“no respon*” or “not respon*” or nonrespon* or non-respon* or
unrespon*)))
# 1 TS=((depress* and ((antidepress* or SSRI* or SNRI* or (serotonin near/3 (uptake or reuptake or re-uptake)) or medication* or
psychotropic or treatment* or respon*) near/2 fail*)))
6 Trial registry search strategy
Types of Study=Interventional
Condition 1= treatment resistant depression
Condition 2= refractory depression
Condition 3= recurrent depression
Condition 4= chronic depression
Search details for 2017 May updates
Component Description
Review area Treating treatment-resistantdepression
Objectives To identify which pharmacological and/or psychological therapies are effective for treatment-
resistant depression
Populations/aspect Adults with treatment-resistant depression
Interventions Pharmacological and/or psychological therapies
Study design RCT/cluster/cross-over
Exclusions Animal studies/editorials/anecdotes/case reports/letters
How the information was searched Databases: MEDLINE, Premedline, Embase, Cochrane Library, PsycInfo, Web of Science
Language: all
Dates: 2016 to date
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(Continued)
Date searched 16 May 2017
Search results MEDLINE/Premedline = 553
Embase = 546
Cochrane = 477
PsycInfo = 246
Web of Science = 673
Total = 2495
Total de-duplicated = 1309
With previously seen references removed = 1193
Trial registers search update June 2017 - 678 (clinicaltrials.gov.), 67 (WHO ICTRP)
C O N T R I B U T I O N S O F A U T H O R S
NWdrafted the protocol, which was finalised following comments from all protocol authors. NW undertook abstract screening for the
primary search, and PD and SI undertook update screening. All review authors contributed to extraction of data from papers included
in the review. SI wrote the first draft of the review, which was commented upon by all review authors. NW is the guarantor of the
review.
CW died in Spring 2018 and the living authors did not make substantive changes to the review beyond this author’s contribution.
D E C L A R A T I O N S O F I N T E R E S T
NW was the Chief Investigator of the National Institute for Health Research HTA-funded CoBalT trial (CBT as an adjunct to
pharmacotherapy for TRD in primary care: ISRCTN38231611), and DK and GL were Principal Investigators. NW, DK, and GL are
authors on two of the studies included in this review (Wiles 2007; Wiles 2016).
PD and SI have no conflicts to declare.
CW is deceased; declarations of interest published in the protocol: “CW has no conflicts to declare”.
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• NIHR CLAHRC West, UK.
This research was supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health
Research and Care West (NIHR CLAHRC West). The views expressed in this article are those of the author(s) and not necessarily
those of the NHS, the NIHR, or the Department of Health and Social Care.
• NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol, UK.
This research was also supported by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust
and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS,
the National Institute for Health Research or the Department of Health and Social Care.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol, we had planned that missing data would be addressed in additional analyses assuming best (all who dropped out had
positive outcomes) and worst (all who dropped out had negative outcomes) case scenarios. However, we later agreed that this was not
necessary because study level data were more robust than participant level data imputations determined by review authors.
We have reported comparison 5 (any psychological therapy vs an attention control) in the methods of the review; this was not stated
in the protocol. This occurred because attention control was listed as a comparator intervention in the section Types of interventions
but was missed in error under planned comparisons in the protocol stage. We found no studies for this comparison.
In the protocol, we had said we were going to calculate and convert the odds ratio (OR) for each study to risk ratio (RR). However,
we found that this was not needed because studies reported event data for dichotomous outcomes in full (only two studies additionally
reported OR). We did calculate OR for each study but found that these values were the same as RR figures, and since the final
presentations were to include RRs, we have chosen to forego presenting ORs.
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